Search

Your search keyword '"Rodriguez Galindo, Carlos"' showing total 1,637 results
Start Over Author "Rodriguez Galindo, Carlos"
1,637 results on '"Rodriguez Galindo, Carlos"'

2. Outcomes of children with well-differentiated fetal hepatoblastoma treated with surgery only: Report from Childrens Oncology Group Trial, AHEP0731.

Author

Vasudevan, Sanjeev, Meyers, Rebecka, Finegold, Milton, López-Terrada, Dolores, Ranganathan, Sarangarajan, Dunn, Stephen, Langham, Max, McGahren, Eugene, Tiao, Greg, Weldon, Christopher, Krailo, Mark, Piao, Jin, Randazzo, Jessica, Towbin, Alexander, BethMcCarville, M, ONeill, Allison, Furman, Wayne, Rodriguez-Galindo, Carlos, Katzenstein, Howard, and Malogolowkin, Marcio

Subjects
Fetal, Hepatoblastoma, Resection, Well-differentiated, Chemotherapy, Adjuvant, Child, Hepatectomy, Hepatoblastoma, Humans, Infant, Liver Neoplasms, Prognosis, Treatment Outcome
Abstract

BACKGROUND: Hepatoblastoma (HB) requires surgical resection for cure, but only 20-30% of patients have resectable disease at diagnosis. Patients who undergo partial hepatectomy at diagnosis have historically received 4-6 cycles of adjuvant chemotherapy; however, those with 100% well-differentiated fetal histology (WDF) have been observed to have excellent outcomes when treated with surgery alone. PATIENTS AND METHODS: Patients on the Childrens Oncology Group non randomized, multicenter phase III study, AHEP0731, were stratified based on Evans stage, tumor histology, and serum alpha-fetoprotein level at diagnosis. Patients were eligible for the very low risk stratum of surgery and observation if they had a complete resection at diagnosis and rapid central histologic review demonstrated HB with 100% WDF histology. RESULTS: A total of 8 eligible patients were enrolled on study between September 14, 2009 and May 28, 2014. Outcome current to 06/30/2020 was used in this analysis. The median age at enrollment was 22.5 months (range: 8-84 months) and the median AFP at enrollment was 714 ng/ml (range: 18-77,747 ng/mL). With a median follow-up of 6.6 years (range: 3.6-9.8 years), the 5-year event-free (EFS) and overall survival (OS) were both 100%. CONCLUSION: This report supports that HB with 100% WDF histology completely resected at diagnosis is curable with surgery only. The development of evidence-based surgical guidelines utilizing criteria based on PRETEXT group, vascular involvement (annotation factors), tumor-specific histology and corresponding biology will be crucial for optimizing which patients are candidates for resection at diagnosis followed by observation. LEVEL OF EVIDENCE: Prognosis study, Level I evidence.

Published
2022

3. Retrospective comparative analysis of two medical evacuation systems for Ukrainian patients affected by war

Author

Adyrov, Mykhaylo V, Alanbousi, Inna, Alexander, Sarah Weeks, Apel, Anna, Avula, Meghana, Bal, Wioletta Anna, Balwierz, Walentyna Aniela, Basset-Salom, Luisa, Bastardo Blanco, Daniel, Bauer, Karolina Jadwiga, Bayazitov, Ildar T, Berlanga, Pablo, Bhakta, Nickhill Hitesh, Bieniek, Katarzyna Anna, Bien, Ewa Iwona, Blackwood, Christopher Andrew, Blair, Sally Jane, Bodak, Khrystyna Ihorivna, Bordeianu, Irina, Bouffet, Eric Eric, Braganca, Joao Maria, Bucurenci, Mihaela Silvia, Budny, Elżbieta Beata, Budzyn, Andrii, Bumgardner, Christopher Carl, Burditt, Raina Nichole, Burnside Clapp, Victoria, Bykov, Viacheslav Valeriyovych, Cañete, Adela, Carnelli, Monica, Cela, Elena, Cepowska, Zuzanna, Chaber, Radoslaw, Cherner-Drieux, Anna, Chubata, Mariya, Clough, Heidi M, Czauderna, Piotr Stefan, Czernicka - Siwecka, Jolanta, Czyzewski, Krzysztof, Dalle, Jean-Hugues, Dashchakovska, Olha, de Koning, Linda A, Dembowska-Baginska, Bozenna Malgorzata, Derwich, Katarzyna, Dirksen, Uta, Dommett, Rachel, Dorosh, Olha Ihorivna, dos Reis Farinha, Nuno Jorge, Drabko, Katarzyna Anna, Dragomir, Monica Desiree, Dutkiewicz, Malgorzata, Dworzak, Michael, Dyma, Sergii Vitaliiovych, Earl, Julian, Eggert, Angelika, English, Martin William, Farren, Becky S, Fedyk, Nataliia Yuriina, Fernández-Teijeiro, Ana, Ferneza, Severyn Romanovych, Foster, Whitney Baer, Fox Irwin, Leeanna Elizabeth, Gałązkowski, Robert Maciej, Ganieva, Galyna, Garanzha, Vasylyna Andriivna, Gelman, Marina S, Godzinski, Jan Krzysztof, Goeres, Anne Françoise, Golban, Rodica, Graetz, Dylan Elizabeth, Greiner, Jeanette, Griksaitis, Michael J, Gupta, Sumit, Hampel, Michal Andrzej, Hastings, Sara Grace, Heenen, Delphine Liliane, Hill, Marcela C, Holiuk, Ihor, Holter, Wolfgang, Hough, Rachael Emma, Hutnik, Lukasz Marek, Irga-Jaworska, Ninela, Istomin, Oleksandr Andriyovych, Ignatova, Anna, Janczar, Szymon Lech, Kacharian, Arman, Kalwak, Krzysztof, Karolczyk, Grażyna Małgorzata, Karpenko, Nataliia Mikolaivna, Katsubo, Halyna Oleksandrivna, Kattamis, Antonis, Kazanowska, Bernarda Jadwiga, Kentsis, Alex, Ketteler, Petra, Kienesberger, Anita, Kiselev, Roman, Kizyma, Zoryana Petrivna, Kliuchkivska, Khrystyna, Klymniuk, Hryhorii Ivanovych, Kolenova, Alexandra, Kolodrubiec, Julia, Kostiuk, Yuliia, Kowalik, Tomasz, Kozlova, Olena Igorivna, Kozubenko, Vladyslav, Kraal, Kathelijne, Kramar, Tetyana Oleksandrivna, Krawczuk-Rybak, Maryna Maryna, Kulemzina, Irina, Kurkowska, Paulina, Kuzyk, Andriy S., Ladenstein, Ruth Lydia, Laguna, Pawel Jozef, Lassaletta, Alvaro, Lehmberg, Kai, Leontieva, Oksana, Liashenko, Serhii, Loizou, Loizos G., Lucchetta, Sonia Anna, Lupo, Matthew William, Lysytsia, Lesya, Lysytsia, Oleksandr, Machnik, Katarzyna Anna, Massimino, Maura, Mainland, Jeff A, Matczak, Katarzyna, Matysiak, Michal Jacek, Mayeur, Pierre, Miller, Beth Anne, Minervina, Anastasia A, Mishkova, Volha, Mizia-Malarz, Agnieszka Joanna, Morales La Madrid, Andres, Moreira, Daniel C, Moreno, Lucas, Moskvin, Vadim P, Mukkada, Sheena Teresa, Muszyńska-Rosłan, Katarzyna Maria, Mykychak, Iryna Volodymyrivna, Niemeyer, Charlotte, Nelson, Akoya Janae', Nogovitsyna, Yuliya, Ociepa, Tomasz, Oltolini, Stefano, Onipko, Nataliia, Pappas, Andrew, Patel, Amit B, Patrahau, Alina Alina, Pauley, Jennifer L., Pavlenko, Yehor Mikhailovich, Pavlovych, Andrij Oleksandrovych, Peregud-Pogorzelski, Jarosław Władyslaw, Perek-Polnik, Marta, Pérez, Vanesa, Pérez-Martínez, Antonio, Pikman, Yana, Pitozzi, Graziano Pitozzi, Portugal, Rui Gentil, Posternak, Victoria Vita, Pleshkan, Viktoriya, Prete, Arcangelo, Pritchard-Jones, Kathy, Raciborska, Anna, Radaelli, Alessandra, Reeves, Tegan Jemma, Reinhardt, Dirk, Reshetnyak, Andrey V, Rider, Andrew Jacob, Rizzari, Carmelo, Rizzi, Damiano Damiano, Rodriguez Hermosillo, Karen Gabriela, Ronenko, Olena Volodymyrivna, Rostkowska, Aneta Olga, Rudko, Liudmyla Yaroslavivna, Sakaan, Firas Mohamed, Sakhar, Nadezhda Aleksandrovna, Salman, Zeena S, Savva, Natallia N., Scaccaglia, Davide, Schaeffer, Elizabeth Hawthorne, Schneider, Carina Ursula, Scobie, Nicole, Semeniuk, Olena Volodymyrivna, Shevchyk, Roksoliana, Shuler, Ana I., Shvets, Stanislav, Sniderman, Liz, Skoczen, Szymon Pawel, Smeal, William John, Sokolowski, Igor, Sonkin, Anna Alexandra, Spolinyak, Andriy, Spota, Andrea, Sramkova, Lucie, Stepanjuk, Alla Ivanivna, Sterba, Jaroslav, Strahm, Brigitte, Styczynski, Jan, Svintsova, Olha, Synyuta, Andriy V, Szczepanski, Tomasz, Szczucinski, Pawel Kukiz, Szmyd, Bartosz Miroslaw, Tasso Cereceda, Maria, Teliuk, Alina, Tomanek, Iwona, Topping, Phoebe, Torrent, Montserrat, Trelińska, Joanna, Troyanovska, Olha Orestivna, Tsurkan, Lyudmila G., Tsymbalyuk-Voloshyn, Iryna, Tyupa, Sergiy Ihorovych, Urasinski, Tomasz Franciszek, Urbanek Dądela, Agnieszka, Vasilieva, Nataliia Jroslavivna, Vasilyeva, Aksana, Verdú-Amorós, Jaime, Vilcu-Bajurean, Natalia, Vinitsky, Leo, Vivtcharenko, Victoria, Vovk, Nelia, Volpe, Giovanni, Vorobel, Oksana Ivanivna, Wachowiak, Jacek Tadeusz, Wasiak, Marcin Slawomir, Wiedower, Lance Allan, Wobst, Natalia, Wuenschel, Lena Isolde, Wysocki, Mariusz Stanislaw, Yurieva, Marina, Zagurska, Anastasiia, Zakharenko, Stanislav S, Zakharenko, Aelita V, Zapotochna, Khrystyna, Zawitkowska, Joanna Emilia, Zecca, Marco, Mueller, Alexandra, Salek, Marta, Oszer, Aleksandra, Evseev, Dmitry, Yakimkova, Taisiya, Wlodarski, Marcin, Vinitsky, Anna, Kizyma, Roman, Pogorelyy, Mikhail, Zuber, Maria, Escalante, Juan, Lipska, Elzbieta, Fendler, Wojciech, Nowicka, Zuzanna, Szyszka, Adam, Rodriguez-Galindo, Carlos, Wise, Paul H., Agulnik, Asya, and Mlynarski, Wojciech

Published
2024
Full Text
View/download PDF

4. Impact of a Regional Pediatric Hematology/Oncology Fellowship Program in Guatemala

Author

Moreira, Daniel C., Garrido, Claudia, Rosado, Roy, Girón, Verónica, Letona, Tomás, Morales, Gerson, Valverde, Patricia, Velásquez, Thelma, Alfaro, Jeanine, Orellana, Elizabeth, Ortega, Miguel Angel, Salguero, Paola, Fox Irwin, Leeanna, Andujar, Allyson, de Alarcón, Pedro A., Luna-Fineman, Sandra, Manco-Johnson, Marilyn, Conter, Valentino, Verna, Marta, Canesi, Marta, Massimino, Maura, Spreafico, Filippo, Ferrari, Andrea, Gassant, Pascale Y., Vásquez, Roberto, Friedrich, Paola, Mack, Ricardo, Ribeiro, Raul, Metzger, Monika L., Rodriguez-Galindo, Carlos, and Antillón-Klussmann, Federico

Published
2024
Full Text
View/download PDF

6. Doxorubicin in combination with cisplatin, 5-flourouracil, and vincristine is feasible and effective in unresectable hepatoblastoma: A Childrens Oncology Group study.

Author

Krailo, Mark, Piao, Jin, Towbin, Alexander, McCarville, M, Tiao, Gregory, Dunn, Stephen, Langham, Max, McGahren, Eugene, Finegold, Milton, Ranganathan, Sarangarajan, Weldon, Christopher, Thompson, Patrick, Trobaugh-Lotrario, Angela, ONeill, Allison, Furman, Wayne, Chung, Nadia, Randazzo, Jessica, Rodriguez-Galindo, Carlos, Meyers, Rebecka, Katzenstein, Howard, and Malogolowkin, Marcio

Subjects
Pretreatment Extent of Disease (PRETEXT), cisplatin, doxorubicin, hepatoblastoma, pediatric liver transplant, pediatric liver tumor, toxicity, Antineoplastic Combined Chemotherapy Protocols, Cisplatin, Doxorubicin, Feasibility Studies, Hepatoblastoma, Humans, Liver Neoplasms, Treatment Outcome, Vincristine
Abstract

BACKGROUND: The Childrens Oncology Group (COG) adopted cisplatin, 5-flourouracil, and vincristine (C5V) as standard therapy after the INT-0098 legacy study showed statistically equivalent survival but less toxicity in comparison with cisplatin and doxorubicin. Subsequent experience demonstrated doxorubicin to be effective in patients with recurrent disease after C5V, and this suggested that it could be incorporated to intensify therapy for patients with advanced disease. METHODS: In this nonrandomized, phase 3 COG trial, the primary aim was to explore the feasibility and toxicity of a novel therapeutic cisplatin, 5-flourouracil, vincristine, and doxorubicin (C5VD) regimen with the addition of doxorubicin to C5V for patients considered to be at intermediate risk. Patients were eligible if they had unresectable, nonmetastatic disease. Patients with a complete resection at diagnosis and local pathologic evidence of small cell undifferentiated histology were also eligible for an assessment of feasibility. RESULTS: One hundred two evaluable patients enrolled between September 14, 2009, and March 12, 2012. Delivery of C5VD was feasible and tolerable: the mean percentages of the target doses delivered were 96% (95% CI, 94%-97%) for cisplatin, 96% (95% CI, 94%-97%) for 5-fluorouracil, 95% (95% CI, 93%-97%) for doxorubicin, and 90% (95% CI, 87%-93%) for vincristine. Toxicity was within expectations, with death as a first event in 1 patient. The most common adverse events were febrile neutropenia (n = 55 [54%]), infection (n = 48 [47%]), mucositis (n = 31 [30%]), hypokalemia (n = 39 [38%]), and elevated aspartate aminotransferase (n = 28 [27%]). The 5-year event-free and overall survival rates for the 93 patients who did not have complete resection at diagnosis were 88% (95% CI, 79%-93%) and 95% (95% CI, 87%-98%), respectively. CONCLUSIONS: The addition of doxorubicin to the previous standard regimen of C5V is feasible, tolerable, and efficacious, and this suggests that C5VD is a good regimen for future clinical trials.

Published
2022

7. Small Cell Undifferentiated Histology Does Not Adversely Affect Outcome in Hepatoblastoma: A Report From the Childrens Oncology Group (COG) AHEP0731 Study Committee.

Author

Trobaugh-Lotrario, Angela, Katzenstein, Howard, Ranganathan, Sarangarajan, Lopez-Terrada, Dolores, Krailo, Mark, Piao, Jin, Chung, Nadia, Randazzo, Jessica, Furman, Wayne, McCarville, Elizabeth, Towbin, Alexander, Tiao, Greg, Dunn, Stephen, Langham, Max, McGahren, Eugene, Feusner, James, Rodriguez-Galindo, Carlos, Meyers, Rebecka, ONeill, Allison, Finegold, Milton, and Malogolowkin, Marcio

Subjects
Adolescent, Antineoplastic Combined Chemotherapy Protocols, Cell Differentiation, Child, Child, Preschool, Disease Progression, Female, Hepatectomy, Hepatoblastoma, Humans, Infant, Infant, Newborn, Liver Neoplasms, Liver Transplantation, Male, Neoplasm Staging, Progression-Free Survival, Retrospective Studies, Risk Assessment, Risk Factors, Time Factors
Abstract

PURPOSE: Small cell undifferentiated (SCU) histology in hepatoblastoma (HB) tumors has historically been associated with a poor prognosis. Tumors from patients enrolled on Childrens Oncology Group (COG) study AHEP0731 underwent institutional and central pathologic review for identification of SCU histology. PATIENTS AND METHODS: Patients with SCU histology identified at the local treating institution who had otherwise low-risk tumors were upstaged to the intermediate-risk treatment stratum, whereas those only identified by retrospective central review were treated per the local institution as low-risk. Patients with otherwise intermediate- or high-risk tumors remained in that treatment stratum, respectively. Central review was to be performed for all tissue samples obtained at any time point. Treatment was per local review, whereas analysis of outcome was based on central review. RESULTS: Thirty-five patients had some elements (1%-25%) of SCU identified on central review of diagnostic specimens. All but two patient tissue sample retained nuclear INI1 expression. The presence of SCU histology did not correlate with age, alpha-fetoprotein level at diagnosis, or sex. The presence of SCU did not affect event-free survival (EFS). EFS at 5 years for patients with low-risk, intermediate-risk, and high-risk with SCU HB was 86% (95% CI, 33 to 98), 81% (95% CI, 57 to 92), and 29% (95% CI, 4 to 61), respectively, compared with EFS at 5 years for patients without SCU enrolled with low-risk, intermediate-risk, and high-risk of 87% (95% CI, 72 to 95), 88% (95% CI, 79 to 94), and 55% (95% CI, 32 to 74; P = .17), respectively. CONCLUSION: The presence of SCU histology in HB does not appear to adversely affect outcome. Future studies should be able to treat patients with SCU HB according to risk stratification without regard to the presence of SCU histology.

Published
2022

8. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Author

Collaborators, GBD 2019 Adolescent Young Adult Cancer, Alvarez, Elysia M, Force, Lisa M, Xu, Rixing, Compton, Kelly, Lu, Dan, Henrikson, Hannah Jacqueline, Kocarnik, Jonathan M, Harvey, James D, Pennini, Alyssa, Dean, Frances E, Fu, Weijia, Vargas, Martina T, Keegan, Theresa HM, Ariffin, Hany, Barr, Ronald D, Erdomaeva, Yana Arturovna, Gunasekera, D Sanjeeva, John-Akinola, Yetunde O, Ketterl, Tyler G, Kutluk, Tezer, Malogolowkin, Marcio Henrique, Mathur, Prashant, Radhakrishnan, Venkatraman, Ries, Lynn Ann Gloeckler, Rodriguez-Galindo, Carlos, Sagoyan, Garik Barisovich, Sultan, Iyad, Abbasi, Behzad, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abbastabar, Hedayat, Abdelmasseh, Michael, Abd-Elsalam, Sherief, Abdoli, Amir, Abebe, Haimanot, Abedi, Aidin, Abidi, Hassan, Abolhassani, Hassan, Ali, Hiwa Abubaker, Abu-Gharbieh, Eman, Achappa, Basavaprabhu, Acuna, Juan Manuel, Adedeji, Isaac Akinkunmi, Adegboye, Oyelola A, Adnani, Qorinah Estiningtyas Sakilah, Advani, Shailesh M, Afzal, Muhammad Sohail, Meybodi, Mohamad Aghaie, Ahadinezhad, Bahman, Ahinkorah, Bright Opoku, Ahmad, Sajjad, Ahmadi, Sepideh, Ahmed, Muktar Beshir, Rashid, Tarik Ahmed, Salih, Yusra Ahmed, Aiman, Wajeeha, Akalu, Gizachew Taddesse, Al Hamad, Hanadi, Alahdab, Fares, AlAmodi, Abdulhadi A, Alanezi, Fahad Mashhour, Alanzi, Turki M, Alem, Adugnaw Zeleke, Alem, Dejene Tsegaye, Alemayehu, Yosef, Alhalaiqa, Fadwa Naji, Alhassan, Robert Kaba, Ali, Saqib, Alicandro, Gianfranco, Alipour, Vahid, Aljunid, Syed Mohamed, Alkhayyat, Motasem, Alluri, Sunitha, Almasri, Nihad A, Al-Maweri, Sadeq Ali, Almustanyir, Sami, Al-Raddadi, Rajaa M, Alvis-Guzman, Nelson, Ameyaw, Edward Kwabena, Amini, Saeed, Amu, Hubert, Ancuceanu, Robert, Andrei, Catalina Liliana, Andrei, Tudorel, Ansari, Fereshteh, Ansari-Moghaddam, Alireza, Anvari, Davood, Anyasodor, Anayochukwu Edward, Arabloo, Jalal, Arab-Zozani, Morteza, Argaw, Ayele Mamo, Arshad, Muhammad, Arulappan, Judie, Aryannejad, Armin, Asemi, Zatollah, Jafarabadi, Mohammad Asghari, Atashzar, Mohammad Reza, Atorkey, and Atreya, Alok

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Prevention, Rare Diseases, Burden of Illness, Pediatric, Cancer, 2.4 Surveillance and distribution, Good Health and Well Being, Adolescent, Adult, Cause of Death, Disability-Adjusted Life Years, Female, Global Burden of Disease, Global Health, Humans, Incidence, Life Expectancy, Male, Mortality, Neoplasms, Prevalence, Risk Factors, Socioeconomic Factors, Young Adult, GBD 2019 Adolescent Young Adult Cancer Collaborators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundIn estimating the global burden of cancer, adolescents and young adults with cancer are often overlooked, despite being a distinct subgroup with unique epidemiology, clinical care needs, and societal impact. Comprehensive estimates of the global cancer burden in adolescents and young adults (aged 15-39 years) are lacking. To address this gap, we analysed results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, with a focus on the outcome of disability-adjusted life-years (DALYs), to inform global cancer control measures in adolescents and young adults.MethodsUsing the GBD 2019 methodology, international mortality data were collected from vital registration systems, verbal autopsies, and population-based cancer registry inputs modelled with mortality-to-incidence ratios (MIRs). Incidence was computed with mortality estimates and corresponding MIRs. Prevalence estimates were calculated using modelled survival and multiplied by disability weights to obtain years lived with disability (YLDs). Years of life lost (YLLs) were calculated as age-specific cancer deaths multiplied by the standard life expectancy at the age of death. The main outcome was DALYs (the sum of YLLs and YLDs). Estimates were presented globally and by Socio-demographic Index (SDI) quintiles (countries ranked and divided into five equal SDI groups), and all estimates were presented with corresponding 95% uncertainty intervals (UIs). For this analysis, we used the age range of 15-39 years to define adolescents and young adults.FindingsThere were 1·19 million (95% UI 1·11-1·28) incident cancer cases and 396 000 (370 000-425 000) deaths due to cancer among people aged 15-39 years worldwide in 2019. The highest age-standardised incidence rates occurred in high SDI (59·6 [54·5-65·7] per 100 000 person-years) and high-middle SDI countries (53·2 [48·8-57·9] per 100 000 person-years), while the highest age-standardised mortality rates were in low-middle SDI (14·2 [12·9-15·6] per 100 000 person-years) and middle SDI (13·6 [12·6-14·8] per 100 000 person-years) countries. In 2019, adolescent and young adult cancers contributed 23·5 million (21·9-25·2) DALYs to the global burden of disease, of which 2·7% (1·9-3·6) came from YLDs and 97·3% (96·4-98·1) from YLLs. Cancer was the fourth leading cause of death and tenth leading cause of DALYs in adolescents and young adults globally.InterpretationAdolescent and young adult cancers contributed substantially to the overall adolescent and young adult disease burden globally in 2019. These results provide new insights into the distribution and magnitude of the adolescent and young adult cancer burden around the world. With notable differences observed across SDI settings, these estimates can inform global and country-level cancer control efforts.FundingBill & Melinda Gates Foundation, American Lebanese Syrian Associated Charities, St Baldrick's Foundation, and the National Cancer Institute.

Published
2022

9. Unification of Efforts to Improve Global Access to Cancer Therapeutics: Report From the 2022/2023 Access to Essential Cancer Medicines Stakeholder Summit

Author

Briercheck, Edward, Pyle, Doug, Adams, Cary, Atun, Rifat, Booth, Christopher, Dent, Jennifer, Garcia-Gonzalez, Pat, Ilbawi, Andre, Jazieh, Abdul Rahman, Kerr, David, Knaul, Felicia, Kobayashi, Emily, Lim, Christopher, Maza, Maurizio, Milner, Danny, Navarro, Maria Fernanda, OʼBrien, Meg, Rodriguez-Galindo, Carlos, Sullivan, Richard, Torode, Julie, Vokes, Everett, and Gralow, Julie

Published
2024
Full Text
View/download PDF

10. Multiple TP53 p.R337H haplotypes and implications for tumor susceptibility

Author

Pinto, Emilia M., Fridman, Cintia, Figueiredo, Bonald C., Salvador, Hector, Teixeira, Manuel R., Pinto, Carla, Pinheiro, Manuela, Kratz, Christian P., Lavarino, Cinzia, Legal, Edith A.M. F., Le, Anh, Kelly, Gregory, Koeppe, Erika, Stoffel, Elena M., Breen, Kelsey, Hahner, Stefanie, Heinze, Britta, Techavichit, Piti, Krause, Amanda, Ogata, Tsutomu, Fujisawa, Yasuko, Walsh, Michael F., Rana, Huma Q., Maxwell, Kara N., Garber, Judy E., Rodriguez-Galindo, Carlos, Ribeiro, Raul C., and Zambetti, Gerard P.

Published
2024
Full Text
View/download PDF

11. Rare tumors: Opportunities and challenges from the Children’s Oncology Group perspective

Author

Schultz, Kris Ann P., Chintagumpala, Murali, Piao, Jin, Chen, Kenneth S., Shah, Rachana, Gartrell, Robyn D., Christison-Lagay, Emily, Pashnakar, Farzana, Berry, Jesse L., O’Neill, Allison F., Vasta, Lauren M., Flynn, Ashley, Mitchell, Sarah G., Seynnaeve, Brittani KN., Rosenblum, Jeremy, Potter, Samara L., Kamihara, Junne, Rodriguez-Galindo, Carlos, Hawkins, Douglas S., and Laetsch, Theodore W.

Published
2023
Full Text
View/download PDF

12. 776: MORTALITY AMONG PEDIATRIC HEMATOLOGY-ONCOLOGY PATIENTS WITH CLINICAL DETERIORATION IN LATIN AMERICA

Author

Agulnik, Asya, Robles Murguia, Maricela, Muniz-Talavera, Hilmarie, Pham, Linh T.D., Cardenas Aguirre, Adolfo, Aragón Joya, Yefry Andrés, Arce, Daniela, Blasco Arriaba, Erika Esther, Costa, Juliana, De Leon, Claudia, Díaz-Coronado, Rosdali, Montalvo, Erika, Miralda Mendez, Scheybi Teresa, Ocampo, Diego, Pineda Urquilla, Estuardo, Aguiar de Paula, Andreia Ribeiro Pereira, Sánchez-Martín, María, Chen, Yichen, Devidas, Meenakshi, and Rodriguez-Galindo, Carlos

Published
2024
Full Text
View/download PDF

13. Treatment-related mortality in children with cancer in low-income and middle-income countries: a systematic review and meta-analysis

Author

Ehrlich, Bella S, McNeil, Michael J, Pham, Linh T D, Chen, Yichen, Rivera, Jocelyn, Acuna, Carlos, Sniderman, Liz, Sakaan, Firas M, Aceituno, Alejandra Mendez, Villegas, Cesar A, Force, Lisa M, Bolous, Nancy S, Wiphatphumiprates, Parima P, Slone, Jeremy S, Carrillo, Angela K, Gillipelli, Srinithya R, Duffy, Caitlyn, Arias, Anita V, Devidas, Meenakshi, Rodriguez-Galindo, Carlos, Mukkada, Sheena, and Agulnik, Asya

Published
2023
Full Text
View/download PDF

14. Effect of paediatric early warning systems (PEWS) implementation on clinical deterioration event mortality among children with cancer in resource-limited hospitals in Latin America: a prospective, multicentre cohort study

Author

Agulnik, Asya, Muniz-Talavera, Hilmarie, Pham, Linh T D, Chen, Yichen, Carrillo, Angela K, Cárdenas-Aguirre, Adolfo, Gonzalez Ruiz, Alejandra, Garza, Marcela, Conde Morelos Zaragoza, Tania Maria, Soberanis Vasquez, Dora Judith, Méndez-Aceituno, Alejandra, Acuña-Aguirre, Carlos, Alfonso-Carreras, Yvania, Alvarez Arellano, Shillel Yahamy, Andrade Sarmiento, Leticia Aradi, Batista, Rosario, Blasco Arriaga, Erika Esther, Calderon, Patricia, Chavez Rios, Mayra, Costa, María Eugenia, Díaz-Coronado, Rosdali, Fing Soto, Ever Amilcar, Gómez García, Wendy Cristhyna, Herrera Almanza, Martha, Juarez Tobías, Maria Susana, León López, Esmeralda Mercedes, López Facundo, Norma Araceli, Martinez Soria, Ruth Angelica, Miller, Kenia, Miralda Méndez, Scheybi Teresa, Mora Robles, Lupe Nataly, Negroe Ocampo, Natalia del Carmen, Noriega Acuña, Berenice, Osuna Garcia, Alejandra, Pérez Alvarado, Carlos M, Pérez Fermin, Clara Krystal, Pineda Urquilla, Estuardo Enrique, Portilla Figueroa, Carlos Andrés, Ríos Lopez, Ligia Estefanía, Rivera Mijares, Jocelyn, Soto Chávez, Verónica, Suarez Soto, Jorge Iván, Teixeira Costa, Juliana, Tejocote Romero, Isidoro, Villanueva Hoyos, Erika Elena, Villegas Pacheco, Marielba, Devidas, Meenakshi, and Rodriguez-Galindo, Carlos

Published
2023
Full Text
View/download PDF

15. Lineage switching of the cellular distribution of BRAFV600E in multisystem Langerhans cell histiocytosis

Author

Milne, Paul, Bomken, Simon, Slater, Olga, Kumar, Ashish, Nelson, Adam, Roy, Somak, Velazquez, Jessica, Mankad, Kshitij, Nicholson, James, Yeomanson, Dan, Grundy, Richard, Kamal, Ahmed, Penn, Anthony, Pears, Jane, Millen, Gerard, Morland, Bruce, Hayden, James, Lam, Jason, Madkhali, Maymoon, MacDonald, Jamie, Singh, Preeti, Pagan, Sarah, Rodriguez-Galindo, Carlos, Minkov, Milen, Donadieu, Jean, Picarsic, Jennifer, Allen, Carl, Bigley, Venetia, and Collin, Matthew

Published
2023
Full Text
View/download PDF

17. Nasopharyngeal Carcinoma

Author

Kontny, Udo, Rodriguez-Galindo, Carlos, Orbach, Daniel, Casanova, Michela, Reaman, Gregory H., Series Editor, Smith, Franklin O., Series Editor, Schneider, Dominik T., editor, Brecht, Ines B., editor, Olson, Thomas A., editor, and Ferrari, Andrea, editor

Published
2022
Full Text
View/download PDF

18. Adrenocortical Tumors in Children

Author

Rodriguez-Galindo, Carlos, Reaman, Gregory H., Series Editor, Smith, Franklin O., Series Editor, Schneider, Dominik T., editor, Brecht, Ines B., editor, Olson, Thomas A., editor, and Ferrari, Andrea, editor

Published
2022
Full Text
View/download PDF

19. The United States

Author

Pashankar, Farzana, Rodriguez-Galindo, Carlos, Reaman, Gregory H., Series Editor, Smith, Franklin O., Series Editor, Schneider, Dominik T., editor, Brecht, Ines B., editor, Olson, Thomas A., editor, and Ferrari, Andrea, editor

Published
2022
Full Text
View/download PDF

20. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)

Author

Jordan, Michael B, Allen, Carl E, Greenberg, Jay, Henry, Michael, Hermiston, Michelle L, Kumar, Ashish, Hines, Melissa, Eckstein, Olive, Ladisch, Stephan, Nichols, Kim E, Rodriguez‐Galindo, Carlos, Wistinghausen, Birte, and McClain, Kenneth L

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rare Diseases, Hematology, Adult, Age of Onset, Child, Clinical Trials as Topic, Diagnosis, Differential, Disease Management, Drug Eruptions, Fetal Diseases, Hematopoietic Stem Cell Transplantation, Humans, Immunocompromised Host, Infant, Infant, Newborn, Liver Failure, Lymphohistiocytosis, Hemophagocytic, Macrophage Activation, Metabolism, Inborn Errors, Neoplasms, Phenotype, Sepsis, hematology, hemophagocytic lymphohistiocytosis, immunology, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis, Paediatrics
Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome of pathologic immune activation, often associated with genetic defects of lymphocyte cytotoxicity. Though a distinctive constellation of features has been described for HLH, diagnosis remains challenging as patients have diverse presentations associated with a variety of triggers. We propose two concepts to clarify how HLH is diagnosed and treated: within the broader syndrome of HLH, "HLH disease" should be distinguished from "HLH disease mimics" and HLH subtypes should be categorized by specific etiologic associations, not the ambiguous dichotomy of "primary" and "secondary." We provide expert-based advice regarding the diagnosis and initiation of treatment for patients with HLH, rooted in improved understanding of its pathophysiology.

Published
2019

21. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial

Author

Katzenstein, Howard M, Langham, Max R, Malogolowkin, Marcio H, Krailo, Mark D, Towbin, Alexander J, McCarville, Mary Beth, Finegold, Milton J, Ranganathan, Sarangarajan, Dunn, Stephen, McGahren, Eugene D, Tiao, Gregory M, O'Neill, Allison F, Qayed, Muna, Furman, Wayne L, Xia, Caihong, Rodriguez-Galindo, Carlos, and Meyers, Rebecka L

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Oncology and Carcinogenesis, Patient Safety, Pediatric, Clinical Trials and Supportive Activities, Pediatric Cancer, Clinical Research, Cancer, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Age Factors, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Child, Child, Preschool, Cisplatin, Disease Progression, Female, Fluorouracil, Hepatectomy, Hepatoblastoma, Humans, Infant, Liver Neoplasms, Male, Neoplasm Staging, Progression-Free Survival, Risk Assessment, Risk Factors, Time Factors, United States, Vincristine, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundHepatoblastoma treatment with curative intent requires surgical resection, but only about a third of newly diagnosed patients with hepatoblastoma have resectable disease at diagnosis. Patients who have upfront resection typically receive a total of 4-6 cycles of adjuvant chemotherapy post-surgery, with the combination of cisplatin, fluorouracil, and vincristine. We aimed to investigate whether event-free survival in children with hepatoblastoma who had complete resection at diagnosis could be maintained with two cycles of adjuvant chemotherapy.MethodsIn this Children's Oncology Group, multicentre, phase 3 trial, patients were enrolled in four risk groups on the basis of Evans surgical stage, tumour histology, and levels of α-fetoprotein at diagnosis to receive risk-adapted therapy. Here, we report on the low-risk stratum of the trial. Eligible patients were younger than 21 years and had histologically confirmed, stage I or II hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology; elevated serum α-fetoprotein level (>100 ng/mL); a complete resection at diagnosis; at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status; and had received no previous chemotherapy or other hepatoblastoma-directed therapy. Patients received two 21-day cycles of cisplatin, fluorouracil, and vincristine within 42 days of resection, consisting of cisplatin (100 mg/m2 per dose or 3·3 mg/kg per dose for children

Published
2019

22. Detection of Relapse by Tumor Markers Versus Imaging in Children and Adolescents With Nongerminomatous Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group

Author

Fonseca, Adriana, Xia, Caihong, Lorenzo, Armando J, Krailo, Mark, Olson, Thomas A, Pashankar, Farzana, Malogolowkin, Marcio H, Amatruda, James F, Billmire, Deborah F, Rodriguez-Galindo, Carlos, Frazier, A Lindsay, and Shaikh, Furqan

Subjects
Cancer, Rare Diseases, Biomedical Imaging, Prevention, Pediatric, Clinical Research, Neurosciences, Pediatric Research Initiative, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, 4.2 Evaluation of markers and technologies, Adolescent, Adult, Biomarkers, Tumor, Child, Child, Preschool, Clinical Trials, Phase III as Topic, Female, Humans, Infant, Infant, Newborn, Male, Neoplasm Recurrence, Local, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Retrospective Studies, Testicular Neoplasms, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo investigate relapse detection methods among children and adolescents with nongerminomatous malignant germ cell tumors (MGCTs) and to determine whether tumor markers alone might be sufficient for surveillance.MethodsWe retrospectively reviewed all patients enrolled in a phase III, single-arm trial for low-risk and intermediate-risk MGCTs. The method used to detect relapse was assessed based on case report forms, tumor markers, imaging, and pathology reports. Relapses were classified into one of two categories on the basis of whether they were (1) detectable by tumor marker elevation or (2) not detectable by tumor markers.ResultsA total of 302 patients were enrolled, and 284 patients had complete data for review. Seven patients had normal tumor markers at initial diagnosis, and none experienced a relapse. At a median follow-up of 5.3 years, 48 patients (16.9%) had experienced a relapse. After central review, 47 of 48 relapses (98%) were detected by tumor marker elevation. Of the 47 patients, 16 (33.3%) had abnormal tumor markers with normal/unknown imaging, 31 patients (64.6%) had abnormal tumor markers with abnormal imaging, and one patient (2.1%) had abnormal imaging with unknown marker levels at relapse.ConclusionTumor marker elevation is a highly sensitive method of relapse surveillance, at least among children and adolescents with tumor marker elevation at initial diagnosis. Eliminating exposure to imaging with ionizing radiation may enhance the safety of relapse surveillance in patients treated for MGCT.

Published
2019

25. Pediatric Adrenocortical Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future Discovery.

Author

O'Neill, Allison F, Ribeiro, Raul C, Pinto, Emilia M, Clay, Michael R, Zambetti, Gerard P, Orr, Brent A, Weldon, Christopher B, and Rodriguez-Galindo, Carlos

Subjects
OVERALL survival, DNA methylation, SURGICAL excision, BOLTS & nuts, SYMPTOMS, ADRENAL tumors
Abstract

Adrenocortical tumors (ACTs) are infrequent neoplasms in children and adolescents and are typically associated with clinical symptoms reflective of androgen overproduction. Pediatric ACTs typically occur in the context of a germline TP53 mutation, can be cured when diagnosed at an early stage, but are difficult to treat when advanced or associated with concurrent TP53 and ATRX alterations. Recent work has demonstrated DNA methylation patterns suggestive of prognostic significance. While current treatment standards rely heavily upon surgical resection, chemotherapy, and hormonal modulation, small cohort studies suggest promise for multi-tyrosine kinases targeting anti-angiogenic pathways or immunomodulatory therapies. Future work will focus on novel risk stratification algorithms and combination therapies intended to mitigate toxicity for patients with perceived low-risk disease while intensifying therapy or accelerating discoveries aimed at improving survival for patients with difficult-to-treat disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019

Author

Alvarez, Elysia M, Force, Lisa M, Xu, Rixing, Compton, Kelly, Lu, Dan, Henrikson, Hannah Jacqueline, Kocarnik, Jonathan M, Harvey, James D, Pennini, Alyssa, Dean, Frances E, Fu, Weijia, Vargas, Martina T, Keegan, Theresa H M, Ariffin, Hany, Barr, Ronald D, Erdomaeva, Yana Arturovna, Gunasekera, D Sanjeeva, John-Akinola, Yetunde O, Ketterl, Tyler G, Kutluk, Tezer, Malogolowkin, Marcio Henrique, Mathur, Prashant, Radhakrishnan, Venkatraman, Ries, Lynn Ann Gloeckler, Rodriguez-Galindo, Carlos, Sagoyan, Garik Barisovich, Sultan, Iyad, Abbasi, Behzad, Abbasi-Kangevari, Mohsen, Abbasi-Kangevari, Zeinab, Abbastabar, Hedayat, Abdelmasseh, Michael, Abd-Elsalam, Sherief, Abdoli, Amir, Abebe, Haimanot, Abedi, Aidin, Abidi, Hassan, Abolhassani, Hassan, Abubaker Ali, Hiwa, Abu-Gharbieh, Eman, Achappa, Basavaprabhu, Acuna, Juan Manuel, Adedeji, Isaac Akinkunmi, Adegboye, Oyelola A, Adnani, Qorinah Estiningtyas Sakilah, Advani, Shailesh M, Afzal, Muhammad Sohail, Aghaie Meybodi, Mohamad, Ahadinezhad, Bahman, Ahinkorah, Bright Opoku, Ahmad, Sajjad, Ahmadi, Sepideh, Ahmed, Muktar Beshir, Ahmed Rashid, Tarik, Ahmed Salih, Yusra, Aiman, Wajeeha, Akalu, Gizachew Taddesse, Al Hamad, Hanadi, Alahdab, Fares, AlAmodi, Abdulhadi A, Alanezi, Fahad Mashhour, Alanzi, Turki M, Alem, Adugnaw Zeleke, Alem, Dejene Tsegaye, Alemayehu, Yosef, Alhalaiqa, Fadwa Naji, Alhassan, Robert Kaba, Ali, Saqib, Alicandro, Gianfranco, Alipour, Vahid, Aljunid, Syed Mohamed, Alkhayyat, Motasem, Alluri, Sunitha, Almasri, Nihad A, Al-Maweri, Sadeq Ali, Almustanyir, Sami, Al-Raddadi, Rajaa M, Alvis-Guzman, Nelson, Ameyaw, Edward Kwabena, Amini, Saeed, Amu, Hubert, Ancuceanu, Robert, Andrei, Catalina Liliana, Andrei, Tudorel, Ansari, Fereshteh, Ansari-Moghaddam, Alireza, Anvari, Davood, Anyasodor, Anayochukwu Edward, Arabloo, Jalal, Arab-Zozani, Morteza, Argaw, Ayele Mamo, Arshad, Muhammad, Arulappan, Judie, Aryannejad, Armin, Asemi, Zatollah, Asghari Jafarabadi, Mohammad, Atashzar, Mohammad Reza, Atorkey, Prince, Atreya, Alok, Attia, Sameh, Aujayeb, Avinash, Ausloos, Marcel, Avila-Burgos, Leticia, Awedew, Atalel Fentahun, Ayala Quintanilla, Beatriz Paulina, Ayele, Alemu Degu, Ayen, Solomon Shitu, Azab, Mohammed A, Azadnajafabad, Sina, Azami, Hiva, Azangou-Khyavy, Mohammadreza, Azari Jafari, Amirhossein, Azarian, Ghasem, Azzam, Ahmed Y, Bahadory, Saeed, Bai, Jianjun, Baig, Atif Amin, Baker, Jennifer L, Banach, Maciej, Bärnighausen, Till Winfried, Barone-Adesi, Francesco, Barra, Fabio, Barrow, Amadou, Basaleem, Huda, Batiha, Abdul-Monim Mohammad, Behzadifar, Masoud, Bekele, Niguss Cherie, Belete, Rebuma, Belgaumi, Uzma Iqbal, Bell, Arielle Wilder, Berhie, Alemshet Yirga, Bhagat, Devidas S, Bhagavathula, Akshaya Srikanth, Bhardwaj, Nikha, Bhardwaj, Pankaj, Bhaskar, Sonu, Bhattacharyya, Krittika, Bhojaraja, Vijayalakshmi S, Bibi, Sadia, Bijani, Ali, Biondi, Antonio, Birara, Setognal, Bjørge, Tone, Bolarinwa, Obasanjo Afolabi, Bolla, Srinivasa Rao, Boloor, Archith, Braithwaite, Dejana, Brenner, Hermann, Bulamu, Norma B, Burkart, Katrin, Bustamante-Teixeira, Maria Teresa, Butt, Nadeem Shafique, Butt, Zahid A, Caetano dos Santos, Florentino Luciano, Cao, Chao, Cao, Yin, Carreras, Giulia, Catalá-López, Ferrán, Cembranel, Francieli, Cerin, Ester, Chakinala, Raja Chandra, Chakraborty, Promit Ananyo, Chattu, Vijay Kumar, Chaturvedi, Pankaj, Chaurasia, Akhilanand, Chavan, Prachi P, Chimed-Ochir, Odgerel, Choi, Jee-Young Jasmine, Christopher, Devasahayam J, Chu, Dinh-Toi, Chung, Michael T, Conde, Joao, Costa, Vera Marisa, Da'ar, Omar B, Dadras, Omid, Dahlawi, Saad M A, Dai, Xiaochen, Damiani, Giovanni, D'Amico, Emanuele, Dandona, Lalit, Dandona, Rakhi, Daneshpajouhnejad, Parnaz, Darwish, Amira Hamed, Daryani, Ahmad, De la Hoz, Fernando Pio, Debela, Sisay Abebe, Demie, Takele Gezahegn G, Demissie, Getu Debalkie, Demissie, Zeleke Geto, Denova-Gutiérrez, Edgar, Derbew Molla, Meseret, Desai, Rupak, Desta, Abebaw Alemayehu, Dhamnetiya, Deepak, Dharmaratne, Samath Dhamminda, Dhimal, Mandira Lamichhane, Dhimal, Meghnath, Dianatinasab, Mostafa, Didehdar, Mojtaba, Diress, Mengistie, Djalalinia, Shirin, Do, Huyen Phuc, Doaei, Saeid, Dorostkar, Fariba, dos Santos, Wendel Mombaque, Drake, Thomas M, Ekholuenetale, Michael, El Sayed, Iman, El Sayed Zaki, Maysaa, El Tantawi, Maha, El-Abid, Hassan, Elbahnasawy, Mostafa Ahmed, Elbarazi, Iffat, Elhabashy, Hala Rashad, Elhadi, Muhammed, El-Jaafary, Shaimaa I, Enyew, Daniel Berhanie, Erkhembayar, Ryenchindorj, Eshrati, Babak, Eskandarieh, Sharareh, Faisaluddin, Mohammed, Fares, Jawad, Farooque, Umar, Fasanmi, Abidemi Omolara, Fatima, Wafa, Ferreira de Oliveira, José Miguel P, Ferrero, Simone, Ferro Desideri, Lorenzo, Fetensa, Getahun, Filip, Irina, Fischer, Florian, Fisher, James L, Foroutan, Masoud, Fukumoto, Takeshi, Gaal, Peter Andras, Gad, Mohamed M, Gaewkhiew, Piyada, Gallus, Silvano, Garg, Tushar, Gebremeskel, Teferi Gebru, Gemeda, Belete Negese Belete, Getachew, Tamiru, Ghafourifard, Mansour, Ghamari, Seyyed-Hadi, Ghashghaee, Ahmad, Ghassemi, Fariba, Ghith, Nermin, Gholami, Ali, Gholizadeh Navashenaq, Jamshid, Gilani, Syed Amir, Ginindza, Themba G, Gizaw, Abraham Tamirat, Glasbey, James C, Goel, Amit, Golechha, Mahaveer, Goleij, Pouya, Golinelli, Davide, Gopalani, Sameer Vali, Gorini, Giuseppe, Goudarzi, Houman, Goulart, Bárbara Niegia Garcia, Grada, Ayman, Gubari, Mohammed Ibrahim Mohialdeen, Guerra, Maximiliano Ribeiro, Guha, Avirup, Gupta, Bhawna, Gupta, Sapna, Gupta, Veer Bala, Gupta, Vivek Kumar, Haddadi, Rasool, Hafezi-Nejad, Nima, Hailu, Alemayehu, Haj-Mirzaian, Arvin, Halwani, Rabih, Hamadeh, Randah R, Hambisa, Mitiku Teshome, Hameed, Sajid, Hamidi, Samer, Haque, Shafiul, Hariri, Sanam, Haro, Josep Maria, Hasaballah, Ahmed I, Hasan, S M Mahmudul, Hashemi, Seyedeh Melika, Hassan, Treska S, Hassanipour, Soheil, Hay, Simon I, Hayat, Khezar, Hebo, Sultan H, Heidari, Golnaz, Heidari, Mohammad, Herrera-Serna, Brenda Yuliana, Herteliu, Claudiu, Heyi, Demisu Zenbaba, Hezam, Kamal, Hole, Michael K, Holla, Ramesh, Horita, Nobuyuki, Hossain, Md Mahbub, Hossain, Mohammad Bellal, Hosseini, Mohammad-Salar, Hosseini, Mostafa, Hosseinzadeh, Ali, Hosseinzadeh, Mehdi, Hostiuc, Mihaela, Hostiuc, Sorin, Househ, Mowafa, Hsairi, Mohamed, Huang, Junjie, Hussein, Nawfal R, Hwang, Bing-Fang, Ibitoye, Segun Emmanuel, Ilesanmi, Olayinka Stephen, Ilic, Irena M, Ilic, Milena D, Innos, Kaire, Irham, Lalu Muhammad, Islam, Rakibul M, Islam, Sheikh Mohammed Shariful, Ismail, Nahlah Elkudssiah, Isola, Gaetano, Iwagami, Masao, Jacob, Louis, Jadidi-Niaragh, Farhad, Jain, Vardhmaan, Jakovljevic, Mihajlo, Janghorban, Roksana, Javadi Mamaghani, Amirreza, Jayaram, Shubha, Jayawardena, Ranil, Jazayeri, Seyed Behzad, Jebai, Rime, Jha, Ravi Prakash, Joo, Tamas, Joseph, Nitin, Joukar, Farahnaz, Jürisson, Mikk, Kaambwa, Billingsley, Kabir, Ali, Kalankesh, Leila R, Kaliyadan, Feroze, Kamal, Zul, Kamath, Ashwin, Kandel, Himal, Kar, Sitanshu Sekhar, Karaye, Ibraheem M, Karimi, Amirali, Kassa, Bekalu Getnet, Kauppila, Joonas H, Kemp Bohan, Phillip M, Kengne, Andre Pascal, Kerbo, Amene Abebe, Keykhaei, Mohammad, Khader, Yousef Saleh, Khajuria, Himanshu, Khalili, Nastaran, Khalili, Neda, Khan, Ejaz Ahmad, Khan, Gulfaraz, Khan, Maseer, Khan, Md Nuruzzaman, Khan, Moien AB, Khanali, Javad, Khayamzadeh, Maryam, Khosravizadeh, Omid, Khubchandani, Jagdish, Khundkar, Roba, Kim, Min Seo, Kim, Yun Jin, Kisa, Adnan, Kisa, Sezer, Kissimova-Skarbek, Katarzyna, Kolahi, Ali-Asghar, Kopec, Jacek A, Koteeswaran, Rajasekaran, Koulmane Laxminarayana, Sindhura Lakshmi, Koyanagi, Ai, Kugbey, Nuworza, Kumar, G Anil, Kumar, Nithin, Kwarteng, Alexander, La Vecchia, Carlo, Lan, Qing, Landires, Iván, Lasrado, Savita, Lauriola, Paolo, Ledda, Caterina, Lee, Sang-woong, Lee, Wei-Chen, Lee, Yeong Yeh, Lee, Yo Han, Leigh, James, Leong, Elvynna, Li, Bingyu, Li, Jiarui, Li, Ming-Chieh, Lim, Stephen S, Liu, Xuefeng, Lobo, Stany W, Loureiro, Joana A, Lugo, Alessandra, Lunevicius, Raimundas, Magdy Abd El Razek, Hassan, Magdy Abd El Razek, Muhammed, Mahmoudi, Morteza, Majeed, Azeem, Makki, Alaa, Male, Shilpa, Malekpour, Mohammad-Reza, Malekzadeh, Reza, Malik, Ahmad Azam, Mamun, Mohammed A, Manafi, Navid, Mansour-Ghanaei, Fariborz, Mansouri, Borhan, Mansournia, Mohammad Ali, Martini, Santi, Masoumi, Seyedeh Zahra, Matei, Clara N, Mathur, Manu Raj, McAlinden, Colm, Mehrotra, Ravi, Mendoza, Walter, Menezes, Ritesh G, Mentis, Alexios-Fotios A, Meretoja, Tuomo J, Mersha, Amanual Getnet, Mesregah, Mohamed Kamal, Mestrovic, Tomislav, Miao Jonasson, Junmei, Miazgowski, Bartosz, Michalek, Irmina Maria, Miller, Ted R, Mingude, Alemu Basazin, Mirmoeeni, Seyyedmohammadsadeq, Mirzaei, Hamed, Misra, Sanjeev, Mithra, Prasanna, Mohammad, Karzan Abdulmuhsin, Mohammadi, Mokhtar, Mohammadi, Seyyede Momeneh, Mohammadian-Hafshejani, Abdollah, Mohammadpourhodki, Reza, Mohammed, Arif, Mohammed, Shafiu, Mohammed, Teroj Abdulrahman, Moka, Nagabhishek, Mokdad, Ali H, Molokhia, Mariam, Momtazmanesh, Sara, Monasta, Lorenzo, Moni, Mohammad Ali, Moradi, Ghobad, Moradi, Yousef, Moradzadeh, Maliheh, Moradzadeh, Rahmatollah, Moraga, Paula, Morrison, Shane Douglas, Mostafavi, Ebrahim, Mousavi Khaneghah, Amin, Mpundu-Kaambwa, Christine, Mubarik, Sumaira, Mwanri, Lillian, Nabhan, Ashraf F, Nagaraju, Shankar Prasad, Nagata, Chie, Naghavi, Mohsen, Naimzada, Mukhammad David, Naldi, Luigi, Nangia, Vinay, Naqvi, Atta Abbas, Narasimha Swamy, Sreenivas, Narayana, Aparna Ichalangod, Nayak, Biswa Prakash, Nayak, Vinod C, Nazari, Javad, Nduaguba, Sabina Onyinye, Negoi, Ionut, Negru, Serban Mircea, Nejadghaderi, Seyed Aria, Nepal, Samata, Neupane Kandel, Sandhya, Nggada, Haruna Asura, Nguyen, Cuong Tat, Nnaji, Chukwudi A, Nosrati, Hamed, Nouraei, Hasti, Nowroozi, Ali, Nuñez-Samudio, Virginia, Nwatah, Vincent Ebuka, Nzoputam, Chimezie Igwegbe, Oancea, Bogdan, Odukoya, Oluwakemi Ololade, Oguntade, Ayodipupo Sikiru, Oh, In-Hwan, Olagunju, Andrew T, Olagunju, Tinuke O, Olakunde, Babayemi Oluwaseun, Oluwasanu, Mojisola Morenike, Omar, Emad, Omar Bali, Ahmed, Ong, Sokking, Onwujekwe, Obinna E, Ortega-Altamirano, Doris V, Otstavnov, Nikita, Otstavnov, Stanislav S, Oumer, Bilcha, Owolabi, Mayowa O, P A, Mahesh, Padron-Monedero, Alicia, Padubidri, Jagadish Rao, Pakshir, Keyvan, Pana, Adrian, Pandey, Anamika, Pardhan, Shahina, Pashazadeh Kan, Fatemeh, Pasovic, Maja, Patel, Jenil R, Pati, Siddhartha, Pattanshetty, Sanjay M, Paudel, Uttam, Pereira, Renato B, Peres, Mario F P, Perianayagam, Arokiasamy, Postma, Maarten J, Pourjafar, Hadi, Pourshams, Akram, Prashant, Akila, Pulakunta, Thejodhar, Qadir, Mirza Muhammad Fahd Fahd, Rabiee, Mohammad, Rabiee, Navid, Radfar, Amir, Radhakrishnan, Raghu Anekal, Rafiee, Ata, Rafiei, Alireza, Rafiei, Sima, Rahim, Fakher, Rahimzadeh, Shadi, Rahman, Mosiur, Rahman, Muhammad Aziz, Rahmani, Amir Masoud, Rajesh, Aashish, Ramezani-Doroh, Vajiheh, Ranabhat, Kamal, Ranasinghe, Priyanga, Rao, Chythra R, Rao, Sowmya J, Rashedi, Sina, Rashidi, Mahsa, Rashidi, Mohammad-Mahdi, Rath, Goura Kishor, Rawaf, David Laith, Rawaf, Salman, Rawal, Lal, Rawassizadeh, Reza, Razeghinia, Mohammad Sadegh, Regasa, Misganu Teshoma, Renzaho, Andre M N, Rezaei, Maryam, Rezaei, Negar, Rezaei, Nima, Rezaeian, Mohsen, Rezapour, Aziz, Rezazadeh-Khadem, Sahba, Riad, Abanoub, Rios Lopez, Ligia Estefania, Rodriguez, Jefferson Antonio Buendia, Ronfani, Luca, Roshandel, Gholamreza, Rwegerera, Godfrey M, Saber-Ayad, Maha Mohamed, Sabour, Siamak, Saddik, Basema, Sadeghi, Erfan, Sadeghian, Saeid, Saeed, Umar, Sahebkar, Amirhossein, Saif-Ur-Rahman, KM, Sajadi, S Mohammad, Salahi, Sarvenaz, Salehi, Sana, Salem, Marwa Rashad, Salimzadeh, Hamideh, Samy, Abdallah M, Sanabria, Juan, Sanmarchi, Francesco, Sarveazad, Arash, Sathian, Brijesh, Sawhney, Monika, Sawyer, Susan M, Saylan, Mete, Schneider, Ione Jayce Ceola, Seidu, Abdul-Aziz, Šekerija, Mario, Sendo, Endalew Gemechu, Sepanlou, Sadaf G, Seylani, Allen, Seyoum, Kenbon, Sha, Feng, Shafaat, Omid, Shaikh, Masood Ali, Shamsoddin, Erfan, Shannawaz, Mohammed, Sharma, Rajesh, Sheikhbahaei, Sara, Shetty, Adithi, Shetty, B Suresh Kumar, Shetty, Pavanchand H, Shin, Jae Il, Shirkoohi, Reza, Shivakumar, K M, Shobeiri, Parnian, Siabani, Soraya, Sibhat, Migbar Mekonnen, Siddappa Malleshappa, Sudeep K, Sidemo, Negussie Boti, Silva, Diego Augusto Santos, Silva Julian, Guilherme, Singh, Achintya Dinesh, Singh, Jasvinder A, Singh, Jitendra Kumar, Singh, Surjit, Sinke, Abiy H, Sintayehu, Yitagesu, Skryabin, Valentin Yurievich, Skryabina, Anna Aleksandrovna, Smith, Lee, Sofi-Mahmudi, Ahmad, Soltani-Zangbar, Mohammad Sadegh, Song, Suhang, Spurlock, Emma Elizabeth, Steiropoulos, Paschalis, Straif, Kurt, Subedi, Ranjeeta, Sufiyan, Mu'awiyyah Babale, Suliankatchi Abdulkader, Rizwan, Sultana, Saima, Szerencsés, Viktória, Szócska, Miklós, Tabaeian, Seidamir Pasha, Tabarés-Seisdedos, Rafael, Tabary, Mohammadreza, Tabuchi, Takahiro, Tadbiri, Hooman, Taheri, Majid, Taherkhani, Amir, Takahashi, Ken, Tampa, Mircea, Tan, Ker-Kan, Tat, Vivian Y, Tavakoli, Ahmad, Tbakhi, Abdelghani, Tehrani-Banihashemi, Arash, Temsah, Mohamad-Hani, Tesfay, Fisaha Haile, Tesfaye, Bekele, Thakur, Jarnail Singh, Thapar, Rekha, Thavamani, Aravind, Thiyagarajan, Arulmani, Thomas, Nihal, Tobe-Gai, Ruoyan, Togtmol, Munkhsaikhan, Tohidast, Seyed Abolfazl, Tohidinik, Hamid Reza, Tolani, Musliu Adetola, Tollosa, Daniel Nigusse, Touvier, Mathilde, Tovani-Palone, Marcos Roberto, Traini, Eugenio, Tran, Bach Xuan, Tran, Mai Thi Ngoc, Tripathy, Jaya Prasad, Tusa, Biruk Shalmeno, Ukke, Gebresilasea Gendisha, Ullah, Irfan, Ullah, Saif, Umapathi, Krishna Kishore, Unnikrishnan, Bhaskaran, Upadhyay, Era, Ushula, Tolassa Wakayo, Vacante, Marco, Valadan Tahbaz, Sahel, Varthya, Shoban Babu, Veroux, Massimiliano, Villeneuve, Paul J, Violante, Francesco S, Vlassov, Vasily, Vu, Giang Thu, Waheed, Yasir, Wang, Ning, Ward, Paul, Weldesenbet, Adisu Birhanu, Wen, Yi Feng, Westerman, Ronny, Winkler, Andrea Sylvia, Wubishet, Befikadu Legesse, Xu, Suowen, Yahyazadeh Jabbari, Seyed Hossein, Yang, Lin, Yaya, Sanni, Yazdi-Feyzabadi, Vahid, Yazie, Taklo Simeneh, Yehualashet, Sisay Shewasinad, Yeshaneh, Alex, Yeshaw, Yigizie, Yirdaw, Birhanu Wubale, Yonemoto, Naohiro, Younis, Mustafa Z, Yousefi, Zabihollah, Yu, Chuanhua, Yunusa, Ismaeel, Zadnik, Vesna, Zahir, Mazyar, Zahirian Moghadam, Telma, Zamani, Mohammad, Zamanian, Maryam, Zandian, Hamed, Zare, Fariba, Zastrozhin, Mikhail Sergeevich, Zastrozhina, Anasthasia, Zhang, Jianrong, Zhang, Zhi-Jiang, Ziapour, Arash, Zoladl, Mohammad, Murray, Christopher J L, Fitzmaurice, Christina, Bleyer, Archie, and Bhakta, Nickhill

Published
2022
Full Text
View/download PDF

27. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.

Author

McClain, Kenneth, Picarsic, Jennifer, Chakraborty, Rikhia, Zinn, Daniel, Lin, Howard, Abhyankar, Harshal, Scull, Brooks, Shih, Albert, Lim, Karen, Eckstein, Olive, Lubega, Joseph, Peters, Tricia, Olea, Walter, Burke, Thomas, Ahmed, Nabil, Hicks, M, Tran, Brandon, Jones, Jeremy, Dauser, Robert, Jeng, Michael, Baiocchi, Robert, Goldman, Stanton, Heym, Kenneth, Wilson, Harry, Carcamo, Benjamin, Kumar, Ashish, Rodriguez-Galindo, Carlos, Whipple, Nicholas, Campbell, Patrick, Murdoch, Geoffrey, Kofler, Julia, Heales, Simon, Malone, Marian, Woltjer, Randy, Quinn, Joseph, Orchard, Paul, Kruer, Michael, Jaffe, Ronald, Manz, Markus, Lira, Sergio, Parsons, D, Merad, Miriam, Man, Tsz-Kwong, Allen, Carl, and Schiff, Deborah

Subjects
BRAF-V600E, CNS neoplasms, Langerhans cell histiocytosis, neurodegeneration, osteopontin, Adolescent, Adult, Biomarkers, Biopsy, Brain, Brain Neoplasms, Child, Child, Preschool, Diagnosis, Differential, Female, Hematopoietic Stem Cells, Histiocytosis, Langerhans-Cell, Humans, Infant, Infant, Newborn, Leukocytes, Mononuclear, MAP Kinase Signaling System, Male, Neurodegenerative Diseases, Osteopontin, Proto-Oncogene Proteins B-raf, Retrospective Studies, Young Adult
Abstract

BACKGROUND: Central nervous system Langerhans cell histiocytosis (CNS-LCH) brain involvement may include mass lesions and/or a neurodegenerative disease (LCH-ND) of unknown etiology. The goal of this study was to define the mechanisms of pathogenesis that drive CNS-LCH. METHODS: Cerebrospinal fluid (CSF) biomarkers including CSF proteins and extracellular BRAFV600E DNA were analyzed in CSF from patients with CNS-LCH lesions compared with patients with brain tumors and other neurodegenerative conditions. Additionally, the presence of BRAFV600E was tested in peripheral mononuclear blood cells (PBMCs) as well as brain biopsies from LCH-ND patients, and the response to BRAF-V600E inhibitor was evaluated in 4 patients with progressive disease. RESULTS: Osteopontin was the only consistently elevated CSF protein in patients with CNS-LCH compared with patients with other brain pathologies. BRAFV600E DNA was detected in CSF of only 2/20 (10%) cases, both with LCH-ND and active lesions outside the CNS. However, BRAFV600E+ PBMCs were detected with significantly higher frequency at all stages of therapy in LCH patients who developed LCH-ND. Brain biopsies of patients with LCH-ND demonstrated diffuse perivascular infiltration by BRAFV600E+ cells with monocyte phenotype (CD14+ CD33+ CD163+ P2RY12- ) and associated osteopontin expression. Three of 4 patients with LCH-ND treated with BRAF-V600E inhibitor experienced significant clinical and radiologic improvement. CONCLUSION: In LCH-ND patients, BRAFV600E+ cells in PBMCs and infiltrating myeloid/monocytic cells in the brain is consistent with LCH-ND as an active demyelinating process arising from a mutated hematopoietic precursor from which LCH lesion CD207+ cells are also derived. Therapy directed against myeloid precursors with activated MAPK signaling may be effective for LCH-ND. Cancer 2018;124:2607-20. © 2018 American Cancer Society.

Published
2018

28. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study

Author

Dicken, Bryan J, Billmire, Deborah F, Krailo, Mark, Xia, Caihong, Shaikh, Furqan, Cullen, John W, Olson, Thomas A, Pashankar, Farzana, Malogolowkin, Marcio H, Amatruda, James F, Rescorla, Frederick J, Egler, Rachel A, Ross, Jonathan H, Rodriguez‐Galindo, Carlos, and Frazier, A Lindsay

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Ovarian Cancer, Cancer, Rare Diseases, Pediatric, Genetics, Prevention, Clinical Research, Adolescent, Adult, Child, Child, Preschool, Disease-Free Survival, Female, Gonadal Dysgenesis, Humans, Infant, Infant, Newborn, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Survival Rate, gonadal dysgenesis, malignant ovarian germ cell tumor, pediatric outcome, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis, Paediatrics
Abstract

In this report, we characterize the timing and behavior of malignant ovarian germ cell tumors (GCTs) in pediatric patients with dysgenetic gonads compared to those with normal gonadal development. Patients from the Children's Oncology Group AGCT0132 with malignant ovarian GCTs were included. Within this population, we sought to identify patients with gonadoblastoma, streak ovaries, or other evidence of gonadal dysgenesis (GD). Patients with malignant GCTs containing one or more of the following histologies-yolk sac tumor, embryonal carcinoma, or choriocarcinoma-were included. Patients were compared with respect to event-free survival (EFS) and overall survival (OS). Nine patients with GD, including seven with gonadoblastoma (mean age, 9.3 years), were compared to 100 non-GD patients (mean age, 12.1 years). The estimated 3-year EFS for patients with GD was 66.7% (95% CI 28.2-87.8%) and for non-GD patients was 88.8% (95% CI 80.2-93.8%). The estimated 3-year OS for patients with GD was 87.5% (95% CI 38.7-98.1%) and for non-GD patients was 97.6% (95% CI of 90.6-99.4%). Patients presenting with nongerminomatous malignant ovarian GCTs in the context of GD have a higher rate of events and death than counterparts with normal gonads. These findings emphasize the importance of noting a contralateral streak ovary or gonadoblastoma at histology for any ovarian GCT and support the recommendation for early bilateral gonadectomy in patients known to have GD with Y chromosome material. In contrast to those with pure dysgerminoma, these patients may represent a high-risk group that requires a more aggressive chemotherapy regimen.

Published
2018

29. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study

Author

Ribelles, A Juan, Balduzzi, Adriana, Elhaddad, Alaa, Casanovas, Alejandra, Garcia Velazquez, Alejandra, Laptsevich, Aliaksandra, Chang, Alicia, F. Sampaio, Alessandra Lamenha, González Prieto, Almudena, Lassaletta, Alvaro, Suarez M, Amaranto, Alcasabas, Ana Patricia, Colita, Anca, Morales La Madrid, Andres, Samudio, Angélica, Tondo, Annalisa, Colombini, Antonella, Kattamis, Antonis, Lopez Facundo, N Araceli, Bhattacharyya, Arpita, Alimi, Aurélia, Phulpin, Aurélie, Vakrmanova, Barbora, Aksoy, Basak A, Brethon, Benoit, Kobuin, Jator Brian, Nolasco Monteiro, Carla, Paillard, Catherine, Vezina, Catherine, Ceyhun, Bozkurt, Hentea, Cristiana, Meazza, Cristina, Ortiz-Morales, Daniel, Solorzano, Roque Daniel, Arce Cabrera, Daniela, Zama, Daniele, Ghosh, Debjani, Ramírez-Rivera, Diana, Calle Jara, Doris A, Janic, Dragana, Rey Helo, Elianneth, Gouache, Elodie, Guerrero Quiroz, Enmanuel, Lopez, Enrique, Thebault, Eric, Maradiegue, Essy, de Berranger, Eva, Ebeid, Fatma S E, Galaverna, Federica, Antillon-Klussmann, Federico, Espinoza Chacur, Felipe, Negro, Fernando Daniel, Carraro, Francesca, Compagno, Francesca, Barriga, Francisco, Tamayo Pedraza, Gabriela, Sanchez Fernandez, Gissela, Naidu, Gita, Tokuc, Gülnur, Alias, Hamidah, B Segocio, Hannah Grace, Boudiaf, Houda, Asetre Luna, Imelda, Maia, Iris, Astigarraga, Itziar, Maza, Ivan, Montoya Vásquez, Jacqueline E, Jazbec, Janez, Lazic, Jelena, Beck Dean, Jeniffer, Rouger-Gaudichon, Jeremie, Contreras González, Johanny Carolina, Huerta Aragonés, Jorge, Fuster, José L, Quintana, Juan, Palma, Julia, Svojgr, Karel, Quintero, Karina, Malic Tudor, Karolina, Georgantzi, Kleopatra, P Schultz, Kris Ann, Ureña Horno, Laura, Fraquelli, Lidia, Meneghello, Linda, Shalaby, Lobna, Macias Mora, Lola L, A Renner, Lorna, Nunes Silva, Luciana, Sisinni, Luisa, Hammad, Mahmoud, Fernández Sanmartín, M, Zubieta A, C Marcela, Drozdowski, María Constanza, Kourti, Maria, Palladino, Marcela María, Miranda Madrazo, Maria R, Poiree, Marilyne, Popova, Marina, Melgar, Mario, Baragaño, Marta, Avilés-Robles, Martha J, Provenzi, Massimo, Mendes Lins, Mecneide, Fatih Orhan, Mehmet, Villarroel, Milena, Jerónimo, Mónica, Varas Palma, Mónica, Rafie Raza, Muhammad, M Justin, Mulindwa, Shaheen, Najma, Domínguez-Pinilla, Nerea, Whipple, Nicholas S, André, Nicolas, Hrusak, Ondrej, Velasco Puyó, Pablo, Zacasa Vargas, Pamela, Olate Mellado, Paola, Yola Gassant, Pascale, Diaz Romero, Paulina, De Santis, Raffaella, Kebudi, Rejin, Boranbayeva, Riza, Vasquez, Roberto, Segura, Romel A., Rosado, Roy Enrique, Gómez, Sandra, Raimbault, Sandra, Gunasekera, Sanjeeva, Makkeyah, Sara M, Buyukkapu Bay, Sema, M Gómez, Sergio, Bouttefroy, Séverine, Islam, Shahnoor, Abouelnaga, Sherif, Torres, Silvio Fabio, Cesaro, Simone, Nunes, Sofia, Rouxinol, Soraia, Bhaumik, Sucharita, Saliyeva, Symbat, Inostroza, Tamara, Velasquez, Thelma, Hnin, Tint Myo, Norén-Nyström, Ulrika, Baretta, Valentina, Jimenez-Antolinez, Yajaira Valentine, Pérez Alonso, Vanesa, Ayer Miller, Vanessa, Gandemer, Virginie, Lotero, Viviana, Mishkova, Volha, Gómez-García, Wendy, Margaryan, Yeva, Syed, Yumna, Mukkada, Sheena, Bhakta, Nickhill, Chantada, Guillermo L, Chen, Yichen, Vedaraju, Yuvanesh, Faughnan, Lane, Homsi, Maysam R, Muniz-Talavera, Hilmarie, Ranadive, Radhikesh, Metzger, Monika, Friedrich, Paola, Agulnik, Asya, Jeha, Sima, Lam, Catherine, Dalvi, Rashmi, Hessissen, Laila, Moreira, Daniel C, Santana, Victor M, Sullivan, Michael, Bouffet, Eric, Caniza, Miguela A, Devidas, Meenakshi, Pritchard-Jones, Kathy, and Rodriguez-Galindo, Carlos

Published
2021
Full Text
View/download PDF

32. Characterization of Pulmonary Metastases in Children With Hepatoblastoma Treated on Childrens Oncology Group Protocol AHEP0731 (The Treatment of Children With All Stages of Hepatoblastoma): A Report From the Childrens Oncology Group.

Author

ONeill, Allison, Towbin, Alexander, Krailo, Mark, Xia, Caihong, Gao, Yun, McCarville, M, Meyers, Rebecka, McGahren, Eugene, Tiao, Greg, Dunn, Stephen, Langham, Max, Weldon, Christopher, Finegold, Milton, Ranganathan, Sarangarajan, Furman, Wayne, Rodriguez-Galindo, Carlos, Katzenstein, Howard, and Malogolowkin, Marcio

Subjects
Adolescent, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Child, Child, Preschool, Cisplatin, Disease-Free Survival, Doxorubicin, Drug Administration Schedule, Female, Fluorouracil, Hepatoblastoma, Humans, Infant, Irinotecan, Liver Neoplasms, Lung Neoplasms, Male, Pneumonectomy, Prognosis, Tomography, X-Ray Computed, Treatment Outcome, Vincristine
Abstract

Purpose To determine whether the pattern of lung nodules in children with metastatic hepatoblastoma (HB) correlates with outcome. Methods Thirty-two patients with metastatic HB were enrolled on Childrens Oncology Group Protocol AHEP0731 and treated with vincristine and irinotecan (VI). Responders to VI received two additional cycles of VI intermixed with six cycles of cisplatin/fluorouracil/vincristine/doxorubicin (C5VD), and nonresponders received six cycles of C5VD alone. Patients were imaged after every two cycles and at the conclusion of therapy. All computed tomography scans and pathology reports were centrally reviewed, and information was collected regarding lung nodule number, size, laterality, timing of resolution, and pulmonary surgery. Results Among the 29 evaluable patients, only 31% met Response Evaluation Criteria in Solid Tumors (RECIST) for measurable metastatic disease. The presence of measurable disease by RECIST, the sum of nodule diameters greater than or equal to the cumulative cohort median size, bilateral disease, and ≥ 10 nodules were each associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065, P = .03, respectively), with nodule number meeting statistical significance. Ten patients underwent pulmonary resection/metastasectomy at various time points, the benefit of which could not be determined because of small patient numbers. Conclusion Children with metastatic HB have a poor prognosis. Overall tumor burden may be an important prognostic factor for these patients. Lesions that fail to meet RECIST size criteria (ie, those < 10 mm) at diagnosis may contain viable tumor, whereas residual lesions at the end of therapy may constitute eradicated tumor/scar tissue. Patients may benefit from risk stratification on the basis of the burden of lung metastatic disease at diagnosis.

Published
2017

33. Upfront window vincristine/irinotecan treatment of high‐risk hepatoblastoma: A report from the Children's Oncology Group AHEP0731 study committee

Author

Katzenstein, Howard M, Furman, Wayne L, Malogolowkin, Marcio H, Krailo, Mark D, McCarville, M Beth, Towbin, Alexander J, Tiao, Greg M, Finegold, Milton J, Ranganathan, Sarangarajan, Dunn, Stephen P, Langham, Max R, McGahren, Eugene D, Rodriguez‐Galindo, Carlos, and Meyers, Rebecka L

Subjects
Cancer, Pediatric Cancer, Pediatric, Rare Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Child, Child, Preschool, Female, Hepatectomy, Hepatoblastoma, Humans, Infant, Irinotecan, Liver Neoplasms, Liver Transplantation, Male, Survival Rate, Vincristine, alpha-Fetoproteins, hepatoblastoma, high-risk, irinotecan, metastatic, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundThe identification of new therapies for high-risk (HR) hepatoblastoma is challenging. Children's Oncology Group study AHEP0731 included a HR stratum to explore the efficacy of novel agents. Herein, the authors report the response rate to the combination of vincristine (V) and irinotecan (I) and the outcome of patients with high-risk hepatoblastoma.MethodsPatients with newly diagnosed metastatic hepatoblastoma or those with a serum α-fetoprotein (AFP) level 1 log10 ) decline in their AFP level. Responders were to receive 2 additional cycles of VI intermixed with 6 cycles of the combination of cisplatin, doxorubicin, 5-fluorouracil, and vincristine (C5VD). Nonresponders were to receive 6 cycles of C5VD alone.ResultsA total of 32 patients with a median age at diagnosis of 26 months (range, 11-159 months) were enrolled between September 2009 and February 2012. Fourteen of 30 evaluable patients were responders (RECIST and AFP in 6 patients, RECIST only in 3 patients, and AFP only in 5 patients). The median AFP decline after 2 cycles of VI for the entire group was 345,565 ng/mL (85% of the initial AFP). The 3-year event-free and overall survival rates were 49% (95% confidence interval, 30%-65%) and 62% (95% confidence interval, 42%-77%), respectively.ConclusionsThe VI combination appears to have substantial activity against HR hepatoblastoma. The ultimate impact of this regimen in improving the outcomes of children with HR hepatoblastoma remains to be determined. Cancer 2017;123:2360-2367. © 2017 American Cancer Society.

Published
2017

34. Addressing regional disparities in pediatric oncology: Results of a collaborative initiative across the Mexican–North American border

Author

Aristizabal, Paula, Fuller, Spencer, Rivera‐Gomez, Rebeca, Ornelas, Mario, Nuno, Laura, Rodriguez‐Galindo, Carlos, Ribeiro, Raul, and Roberts, William

Subjects
Paediatrics, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Pediatric, Rare Diseases, Cancer, Pediatric Cancer, Clinical Research, Good Health and Well Being, Adolescent, California, Child, Child, Preschool, Delivery of Health Care, Female, Global Health, Humans, Infant, Infant, Newborn, Male, Mexico, Neoplasms, Socioeconomic Factors, global health, international collaboration, international oncology, pediatric cancer disparities, pediatric oncology, US-Mexico border, U.S.-Mexico border, Clinical Sciences, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundCancer is emerging as a major cause of childhood mortality in low- and middle-income countries. In Mexico, cancer is the number one cause of death in children aged 5-14. Until recently, many children with cancer from Baja California, Mexico, went untreated. We reasoned that an initiative inspired by the St. Jude Children's Research Hospital (SJCRH) "twinning" model could successfully be applied to the San Diego-Tijuana border region. In 2008, a twinning project was initiated by Rady Children's Hospital, SJCRH, and the General Hospital Tijuana (GHT). Our aim was to establish a pediatric oncology unit in a culturally sensitive manner, adapted to the local healthcare system.ProcedureAn initial assessment revealed that despite existence of basic hospital infrastructure at the GHT, the essential elements of a pediatric cancer unit were lacking, including dedicated space, trained staff, and uniform treatment. A 5-year action plan was designed to offer training, support the staff financially, and improve the infrastructure.ResultsAfter 7 years, accomplishments include the opening of a new inpatient unit with updated technology, fully trained staff, and a dedicated, interdisciplinary team. Over 700 children have benefited from accurate diagnosis and treatment.ConclusionsInitiatives that implement long-term partnerships between institutions along the Mexican-North American border can be highly effective in establishing successful pediatric cancer control programs. The geographic proximity facilitated accelerated training and close monitoring of project development. Similar initiatives across other disciplines may benefit additional patients and synergize with pediatric oncology programs to reduce health disparities in underserved areas.

Published
2017

35. Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group

Author

Shaikh, Furqan, Cullen, John W, Olson, Thomas A, Pashankar, Farzana, Malogolowkin, Marcio H, Amatruda, James F, Villaluna, Doojduen, Krailo, Mark, Billmire, Deborah F, Rescorla, Frederick J, Egler, Rachel A, Dicken, Bryan J, Ross, Jonathan H, Schlatter, Marc, Rodriguez-Galindo, Carlos, and Frazier, A Lindsay

Subjects
Pediatric, Rare Diseases, Cancer, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Child, Cisplatin, Disease-Free Survival, Drug Administration Schedule, Etoposide, Female, Humans, Male, Neoplasm Staging, Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Prospective Studies, Risk Factors, Testicular Neoplasms, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Purpose To investigate whether event-free survival (EFS) can be maintained among children and adolescents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplatin, etoposide, and bleomycin (PEb) is reduced from four to three cycles and compressed from 5 to 3 days per cycle. Patients and Methods In a phase 3, single-arm trial, patients with IR MGCT (stage II-IV testicular, II-III ovarian, I-II extragonadal, or stage I gonadal tumors with subsequent recurrence) received three cycles of PEb. A parametric comparator model specified that the observed EFS rate should not be significantly < 92%. As recommended for trials that test a reduction of therapy, a one-sided P value ≤ .10 was used to indicate statistical significance. In a post hoc analysis, we also compared results to the EFS rate of comparable patients treated with four cycles of PEb in two prior studies. Results Among 210 eligible patients enrolled from 2003 to 2011, 4-year EFS (EFS4) rate was 89% (95% confidence interval, 83% to 92%), which was significantly lower than the 92% threshold of the comparison model ( P = .08). Among 181 newly diagnosed patients, the EFS4 rate was 87%, compared with 92% for 92 comparable children in the historical cohort ( P = .15). The EFS4 rate was significantly associated with stage (stage I, 100%; stage II, 92%; stage III, 85%; and stage IV, 54%; P < .001). Conclusion The EFS rate for children with IR MGCT observed after three cycles of PEb was less than that of a prespecified parametric model, particularly for patients with higher-stage tumors. These data do not support a reduction in the number of cycles of PEb from four to three. However, further investigation of a reduction in the number of cycles for patients with lower-stage tumors is warranted.

Published
2017

38. Multinational Retrospective Central Pathology Review of Neuroblastoma: Lessons Learned to Establish a Regional Pathology Referral Center in Resource-Limited Settings

Author

Santiago, Teresa, Polanco, Ana C., Fuentes-Alabi, Soad, Hayes, Caleb, Orellana, Elizabeth, Gomero, Belkis, Gonzalez, Mazlova Toledo, Ruiz, Eduviges, Duran, Moises Espino, Rodriguez-Galindo, Carlos, and Metzger, Monika

Subjects
Regional medical programs -- Methods, Practice guidelines (Medicine), Medical referral -- Methods, Pathological laboratories -- Alliances and partnerships -- Quality management, Hospitals, Voluntary -- Regional alliances, Neuroblastoma -- Diagnosis, Health
Abstract

* Context.--Several countries of the Central America and Caribbean region have been sharing regional neuroblastoma (NB) treatment guidelines. However, there is no standardization in the diagnosis, subclassification, or tumor biology to aid in the risk stratification of these patients. Objective.--To examine the histology and assess the accuracy of the local pathology reports; to evaluate the usefulness of manual MYCN immunohistochemistry (IHC); and to use NB as a model to identify the needs to establish a central pathology review (CPR) program in this region. Design.--A retrospective CPR of specimens derived from patients with a diagnosis of NB and treated under the regional NB guidelines between 2012 and 2017 was conducted, allowing for a comparison between local diagnoses and the CPR diagnoses. Manual MYCN IHC was performed in the confirmed NB specimens and the results compared with known fluorescence in situ hybridization or automated IHC results, when available. Results.--The 156 specimens reviewed included 460 blocks and 183 original slides. Neuroblastoma was confirmed in 138 samples (88.5%), but low concordance rates for Shimada classification (n = 39; 25.0%), mitotic-karyorrhectic index (n = 4; 2.5%), and International Neuroblastoma Pathology Classification (n = 18; 11.5%) were noted. Manual MYCN IHC performed on 120 specimens showed conclusive results in 89.2% (28 positive, 23.4%; 79 negative, 65.8%) and questionable results in 10.8% (n = 13). Conclusions.--This retrospective CPR highlights the need for a CPR program to serve this region, to ensure correct diagnosis and subclassification of NB, and to provide manual MYCN IHC--with reflexing to fluorescence in situ hybridization, if questionable. This approach can further regional collaboration, enhance test utilization, and ultimately improve patients' outcomes. doi: 10.5858/arpa.2019-0570-0A, Established in 1998, the Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA) is a consortium of pediatric oncology centers from Central American and Caribbean region countries, including Nicaragua, Guatemala, El [...]

Published
2021
Full Text
View/download PDF

40. Sustainable care for children with cancer: a Lancet Oncology Commission

Author

Atun, Rifat, Bhakta, Nickhill, Denburg, Avram, Frazier, A Lindsay, Friedrich, Paola, Gupta, Sumit, Lam, Catherine G, Ward, Zachary J, Yeh, Jennifer M, Allemani, Claudia, Coleman, Michel P, Di Carlo, Veronica, Loucaides, Eva, Fitchett, Elizabeth, Girardi, Fabio, Horton, Susan E, Bray, Freddie, Steliarova-Foucher, Eva, Sullivan, Richard, Aitken, Joanne F, Banavali, Shripad, Binagwaho, Agnes, Alcasabas, Patricia, Antillon, Federico, Arora, Ramandeep S, Barr, Ronald D, Bouffet, Eric, Challinor, Julia, Fuentes-Alabi, Soad, Gross, Thomas, Hagander, Lars, Hoffman, Ruth I, Herrera, Cristian, Kutluk, Tezer, Marcus, Karen J, Moreira, Claude, Pritchard-Jones, Kathy, Ramirez, Oscar, Renner, Lorna, Robison, Leslie L, Shalkow, Jaime, Sung, Lillian, Yeoh, Allen, and Rodriguez-Galindo, Carlos

Published
2020
Full Text
View/download PDF

42. Understanding treatment recommendations at diagnosis of advanced cancer in pediatric oncology: The need to explore decision‐making challenges globally

Author

Force, Lisa M., primary, Hlatywayo, Loyce, additional, Salek, Marta, additional, Bhakta, Manoo, additional, Bonilla, Miguel, additional, Kaye, Erica C., additional, Rodriguez‐Galindo, Carlos, additional, Baker, Justin N., additional, Bhakta, Nickhill, additional, and Chitsike, Inam, additional

Published
2024
Full Text
View/download PDF

44. Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

Author

Merchant, Melinda, Wright, Matthew, Baird, Kristin, Wexler, Leonard, Rodriguez-Galindo, Carlos, Bernstein, Donna, Delbrook, Cindy, Lodish, Maya, Bishop, Rachel, Wolchok, Jedd, Streicher, Howard, and Mackall, Crystal

Subjects
Adolescent, Adult, Antibodies, Monoclonal, Antineoplastic Agents, Brain, Child, Child, Preschool, Combined Modality Therapy, Drug Monitoring, Female, Humans, Immunomodulation, Ipilimumab, Magnetic Resonance Imaging, Male, Neoplasms, Retreatment, Treatment Outcome, Young Adult
Abstract

PURPOSE: Ipilimumab is a first-in-class immune checkpoint inhibitor approved for treatment of metastatic melanoma but not studied in children until this phase I protocol. EXPERIMENTAL DESIGN: This study examined safety, pharmacokinetics, and immunogenicity, and immune correlates of ipilimumab administered to subjects ≤21 years old with recurrent or progressive solid tumors. Dose escalation cohorts received 1, 3, 5, or 10 mg/m(2) intravenously every 3 weeks in a 3 + 3 design. Response was assessed after 6 weeks and 12 weeks, and then every 3 months. Treatment was continued until disease progression or unacceptable toxicity. RESULTS: Thirty-three patients received 72 doses of ipilimumab. Patients enrolled had melanoma (n = 12), sarcoma (n = 17), or other refractory solid tumors (n = 4). Immune-related adverse events included pancreatitis, pneumonitis, colitis, endocrinopathies, and transaminitis with dose-limiting toxicities observed at 5 and 10 mg/kg dose levels. Pharmacokinetics revealed a half-life of 8 to 15 days. At day 21, subjects had increased levels of cycling T cells, but no change in regulatory T-cell populations. Six subjects had confirmed stable disease for 4 to 10 cycles (melanoma, osteosarcoma, clear cell sarcoma, and synovial sarcoma). CONCLUSIONS: Ipilimumab was safely administered to pediatric patients using management algorithms for immune-related toxicities. The spectrum of immune-related adverse events is similar to those described in adults; however, many of the pediatric toxicities were evident after a single dose. Although no objective tumor regressions were observed with ipilimumab as a single agent, subjects with immune-related toxicities had an increased overall survival compared with those who showed no evidence of breaking tolerance.

Published
2016

45. 776: MORTALITY AMONG PEDIATRIC HEMATOLOGY-ONCOLOGY PATIENTS WITH CLINICAL DETERIORATION IN LATIN AMERICA

Author

Agulnik, Asya, primary, Robles Murguia, Maricela, additional, Muniz-Talavera, Hilmarie, additional, Pham, Linh T.D., additional, Cardenas Aguirre, Adolfo, additional, Aragón Joya, Yefry Andrés, additional, Arce, Daniela, additional, Blasco Arriaba, Erika Esther, additional, Costa, Juliana, additional, De Leon, Claudia, additional, Díaz-Coronado, Rosdali, additional, Montalvo, Erika, additional, Miralda Mendez, Scheybi Teresa, additional, Ocampo, Diego, additional, Pineda Urquilla, Estuardo, additional, Aguiar de Paula, Andreia Ribeiro Pereira, additional, Sánchez-Martín, María, additional, Chen, Yichen, additional, Devidas, Meenakshi, additional, and Rodriguez-Galindo, Carlos, additional

Published
2023
Full Text
View/download PDF

46. Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine

Author

Salek, Marta, primary, Mueller, Alexandra, additional, Alanbousi, Inna, additional, Cepowska, Zuzanna, additional, Dutkiewicz, Malgorzata, additional, Earl, Julian, additional, Evseev, Dmitry, additional, Kizyma, Roman, additional, Kliuchkivska, Khrystyna, additional, Kolodrubiec, Julia, additional, Matczak, Katarzyna, additional, Nogovitsyna, Yuliya, additional, Oszer, Aleksandra, additional, Pogorelyy, Mikhail, additional, Raciborska, Anna, additional, Rasul, Suheir, additional, Sokolowski, Igor, additional, Sopilnyak, Andriy, additional, Vinitsky, Anna, additional, Wlodarski, Marcin W, additional, Wobst, Natalia, additional, Yakimkova, Taisiya, additional, Rodriguez-Galindo, Carlos, additional, Wise, Paul H, additional, Mlynarski, Wojciech, additional, Agulnik, Asya, additional, Alexander, Sarah Weeks, additional, Apel, Anna, additional, Adyrov, Mykhaylo V, additional, Avula, Meghana, additional, Bal, Wioletta Anna, additional, Balwierz, Walentyna Aniela, additional, Basset-Salom, Luisa, additional, Bastardo Blanco, Daniel, additional, Bauer, Karolina Jadwiga, additional, Bayazitov, Ildar T, additional, Berlanga, Pablo, additional, Bhakta, Nickhill Hitesh, additional, Bieniek, Katarzyna Anna, additional, Bien, Ewa Iwona, additional, Blackwood, Christopher Andrew, additional, Blair, Sally Jane, additional, Bodak, Khrystyna Ihorivna, additional, Bordeianu, Irina, additional, Bouffet, Eric, additional, Braganca, Joao Maria, additional, Bucurenci, Mihaela Silvia, additional, Budny, Elżbieta Beata, additional, Budzyn, Andrii, additional, Bumgardner, Christopher Carl, additional, Burditt, Raina Nichole, additional, Burnside Clapp, Victoria, additional, Bykov, Viacheslav Valeriyovych, additional, Cañete, Adela, additional, Carnelli, Monica, additional, Cela, Elena, additional, Chaber, Radoslaw, additional, Cherner-Drieux, Anna, additional, Chubata, Mariya, additional, Clough, Heidi M, additional, Czauderna, Piotr Stefan, additional, Czernicka - Siwecka, Jolanta, additional, Czyzewski, Krzysztof, additional, Dalle, Jean-Hugues, additional, Dashchakovska, Olha, additional, de Koning, Linda A, additional, Dembowska-Baginska, Bozenna Malgorzata, additional, Derwich, Katarzyna, additional, Dirksen, Uta, additional, Dommett, Rachel, additional, Dorosh, Olha Ihorivna, additional, dos Reis Farinha, Nuno Jorge, additional, Drabko, Katarzyna Anna, additional, Dragomir, Monica Desiree, additional, Dworzak, Michael, additional, Dyma, Sergii Vitaliiovych, additional, Eggert, Angelika, additional, English, Martin William, additional, Farren, Becky S, additional, Fedyk, Nataliia Yuriina, additional, Fernández-Teijeiro, Ana, additional, Ferneza, Severyn Romanovych, additional, Foster, Whitney Baer, additional, Fox Irwin, Leeanna Elizabeth, additional, Gałązkowski, Robert Maciej, additional, Ganieva, Galyna, additional, Garanzha, Vasylyna Andriivna, additional, Gelman, Marina S, additional, Godzinski, Jan Krzysztof, additional, Goeres, Anne Françoise, additional, Golban, Rodica, additional, Graetz, Dylan Elizabeth, additional, Greiner, Jeanette, additional, Griksaitis, Michael J, additional, Gupta, Sumit, additional, Hampel, Michal Andrzej, additional, Hastings, Sara Grace, additional, Heenen, Delphine Liliane, additional, Hill, Marcela C, additional, Holiuk, Ihor, additional, Holter, Wolfgang, additional, Hough, Rachael Emma, additional, Hutnik, Lukasz Marek, additional, Irga-Jaworska, Ninela, additional, Istomin, Oleksandr Andriyovych, additional, Ignatova, Anna, additional, Janczar, Szymon Lech, additional, Kacharian, Arman, additional, Kalwak, Krzysztof, additional, Karolczyk, Grażyna Małgorzata, additional, Karpenko, Nataliia Mikolaivna, additional, Katsubo, Halyna Oleksandrivna, additional, Kattamis, Antonis, additional, Kazanowska, Bernarda Jadwiga, additional, Kentsis, Alex, additional, Ketteler, Petra, additional, Kienesberger, Anita, additional, Kiselev, Roman, additional, Kizyma, Zoryana Petrivna, additional, Klymniuk, Hryhorii Ivanovych, additional, Kolenova, Alexandra, additional, Kostiuk, Yuliia, additional, Kowalik, Tomasz, additional, Kozlova, Olena Igorivna, additional, Kozubenko, Vladyslav, additional, Kraal, Kathelijne, additional, Kramar, Tetyana Oleksandrivna, additional, Krawczuk-Rybak, Maryna Maryna, additional, Kulemzina, Irina, additional, Kurkowska, Paulina, additional, Kuzyk, Andriy S., additional, Ladenstein, Ruth Lydia, additional, Laguna, Pawel Jozef, additional, Lassaletta, Alvaro, additional, Lehmberg, Kai, additional, Leontieva, Oksana, additional, Liashenko, Serhii, additional, Loizou, Loizos G., additional, Lucchetta, Sonia Anna, additional, Lupo, Matthew William, additional, Lysytsia, Lesya, additional, Lysytsia, Oleksandr, additional, Machnik, Katarzyna Anna, additional, Massimino, Maura, additional, Mainland, Jeff A, additional, Matysiak, Michal Jacek, additional, Mayeur, Pierre, additional, Miller, Beth Anne, additional, Minervina, Anastasia A, additional, Mishkova, Volha, additional, Mizia-Malarz, Agnieszka Joanna, additional, Morales La Madrid, Andres, additional, Moreira, Daniel C, additional, Moreno, Lucas, additional, Moskvin, Vadim P, additional, Mukkada, Sheena Teresa, additional, Muszyńska-Rosłan, Katarzyna Maria, additional, Mykychak, Iryna Volodymyrivna, additional, Niemeyer, Charlotte, additional, Nelson, Akoya Janae', additional, Ociepa, Tomasz, additional, Oltolini, Stefano, additional, Onipko, Nataliia, additional, Pappas, Andrew, additional, Patel, Amit B, additional, Patrahau, Alina Alina, additional, Pauley, Jennifer L., additional, Pavlenko, Yehor Mikhailovich, additional, Pavlovych, Andrij Oleksandrovych, additional, Peregud-Pogorzelski, Jarosław Władysław, additional, Perek-Polnik, Marta, additional, Pérez, Vanesa, additional, Pérez-Martínez, Antonio, additional, Pikman, Yana, additional, Pitozzi, Graziano Pitozzi, additional, Portugal, Rui Gentil, additional, Posternak, Victoria Vita, additional, Pleshkan, Viktoriya, additional, Prete, Arcangelo, additional, Pritchard-Jones, Kathy, additional, Radaelli, Alessandra, additional, Reeves, Tegan Jemma, additional, Reinhardt, Dirk, additional, Reshetnyak, Andrey V, additional, Rider, Andrew Jacob, additional, Rizzari, Carmelo, additional, Rizzi, Damiano Damiano, additional, Rodriguez Hermosillo, Karen Gabriela, additional, Ronenko, Olena Volodymyrivna, additional, Rostkowska, Aneta Olga, additional, Rudko, Liudmyla Yaroslavivna, additional, Sakaan, Firas Mohamed, additional, Sakhar, Nadezhda Aleksandrovna, additional, Salman, Zeena S, additional, Savva, Natallia N, additional, Scaccaglia, Davide, additional, Schaeffer, Elizabeth Hawthorne, additional, Schneider, Carina Ursula, additional, Scobie, Nicole, additional, Semeniuk, Olena Volodymyrivna, additional, Shevchyk, Roksoliana, additional, Shuler, Ana, additional, Shvets, Stanislav, additional, Sniderman, Liz, additional, Skoczen, Szymon Pawel, additional, Smeal, William John, additional, Sonkin, Anna Alexandra, additional, Spota, Andrea, additional, Sramkova, Lucie, additional, Stepanjuk, Alla Ivanivna, additional, Sterba, Jaroslav, additional, Strahm, Brigitte, additional, Styczynski, Jan, additional, Svintsova, Olha, additional, Synyuta, Andriy V, additional, Szczepanski, Tomasz, additional, Szczucinski, Paweł Kukiz, additional, Szmyd, Bartosz Miroslaw, additional, Tasso Cereceda, Maria, additional, Teliuk, Alina, additional, Tomanek, Iwona, additional, Topping, Phoebe, additional, Torrent, Montserrat, additional, Trelińska, Joanna, additional, Troyanovska, Olha Orestivna, additional, Tsurkan, Lyudmila G., additional, Tsymbalyuk-Voloshyn, Iryna, additional, Tyupa, Sergiy Ihorovych, additional, Urasinski, Tomasz Franciszek, additional, Urbanek Dądela, Agnieszka, additional, Vasilieva, Nataliia Jroslavivna, additional, Vasilyeva, Aksana, additional, Verdú-Amorós, Jaime, additional, Vilcu-Bajurean, Natalia, additional, Vinitsky, Leo, additional, Vivtcharenko, Victoria, additional, Vovk, Nelia, additional, Volpe, Giovanni, additional, Vorobel, Oksana Ivanivna, additional, Wachowiak, Jacek Tadeusz, additional, Wasiak, Marcin Sławomir, additional, Wiedower, Lance Allan, additional, Wuenschel, Lena Isolde, additional, Wysocki, Mariusz Stanislaw, additional, Yurieva, Marina, additional, Zagurska, Anastasiia, additional, Zakharenko, Stanislav S, additional, Zakharenko, Aelita V, additional, Zapotochna, Khrystyna, additional, Zawitkowska, Joanna Emilia, additional, and Zecca, Marco, additional

Published
2023
Full Text
View/download PDF

49. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017

Author

Force, Lisa M., Abdollahpour, Ibrahim, Advani, Shailesh M, Agius, Dominic, Ahmadian, Elham, Alahdab, Fares, Alam, Tahiya, Alebel, Animut, Alipour, Vahid, Allen, Christine A., Almasi-Hashiani, Amir, Alvarez, Elysia M, Amini, Saeed, Amoako, Yaw Ampem, Anber, Nahla Hamed, Arabloo, Jalal, Artaman, Al, Atique, Suleman, Awasthi, Ashish, Bagherzadeh, Mojtaba, Basaleem, Huda, Bekru, Eyasu Tamru, Bijani, Ali, Bogale, Kassawmar Angaw, Car, Mate, Carvalho, Félix, Castro, Clara, Catalá-López, Ferrán, Chu, Dinh-Toi, Costa, Vera M, Darwish, Amira Hamed, Demeke, Feleke Mekonnen, Demis, Asmamaw Bizuneh, Demoz, Gebre Teklemariam, Dharmaratne, Samath Dhamminda, Do, Huyen Phuc, Doan, Linh Phuong, Dubey, Manisha, Eftekhari, Aziz, El-Khatib, Ziad, Emamian, Mohammad Hassan, Farhangi, Mahdieh Abbasalizad, Fernandes, Eduarda, Fischer, Florian, Fouladi Fard, Reza, Friedrich, Paola M, Fukumoto, Takeshi, Gedefaw, Getnet Azeze, Ghashghaee, Ahmad, Gholamian, Asadollah, Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hamidi, Samer, Harvey, James D., Hassen, Hamid Yimam, Hay, Simon I., Hoang, Chi Linh, Hole, Michael K., Horita, Nobuyuki, Hosseini, Seyyed Nasrollah, Hosseinzadeh, Mehdi, Hsairi, Mohamed, Hudson, Melissa Maria, Innos, Kaire, Jalilian, Farzad, James, Spencer L., Kasaeian, Amir, Kassa, Tesfaye Dessale, Kassebaum, Nicholas J, Keiyoro, Peter Njenga, Khader, Yousef Saleh, Khubchandani, Jagdish, Kianipour, Neda, Kirby, Jeannette, Kisa, Adnan, Kisa, Sezer, Kocarnik, Jonathan M, Lauriola, Paolo, Lopez, Alan D, Mägi, Margit, Malik, Manzoor Ahmad, Manafi, Ali, Manafi, Navid, Mansournia, Mohammad Ali, Massenburg, Benjamin Ballard, Mehta, Varshil, Meles, Hagazi Gebre, Meretoja, Tuomo J, Mestrovic, Tomislav, Mir, Seyed Mostafa, Mirzaei-Alavijeh, Mehdi, Mohammad, Dara K., Mohammad Darwesh, Aso, Mohammad Gholi Mezerji, Naser, Mohammadibakhsh, Roghayeh, Mohammadoo-Khorasani, Milad, Mokdad, Ali H, Moodley, Yoshan, Moosazadeh, Mahmood, Moossavi, Maryam, Moradpour, Farhad, Morrison, Shane Douglas, Muchie, Kindie Fentahun, Naghavi, Mohsen, Nazari, Javad, Ngunjiri, Josephine W., Nguyen, Cuong Tat, Nguyen, Long Hoang, Nguyen, Son Hoang, Nguyen, Trang Huyen, Nixon, Molly R, Olagunju, Andrew T, Olagunju, Tinuke O, Ong, Sok King, Paapsi, Keiu, Pennini, Alyssa, Pereira, David M., Pillay, Julian David, Qorbani, Mostafa, Rabiee, Mohammad, Rabiee, Navid, Raoofi, Samira, Rawaf, David Laith, Rawaf, Salman, Reiner, Robert C, Rezaei, Nima, Rezapour, Aziz, Roba, Kedir Teji, Robison, Les L., Rodriguez-Galindo, Carlos, Roshandel, Gholamreza, Safiri, Saeid, Salahshoor, Mohamadreza, Salehi Zahabi, Saleh, Samy, Abdallah M., Santric Milicevic, Milena M, Satpathy, Maheswar, Sawyer, Susan M, Seyedmousavi, Seyedmojtaba, Shabaninejad, Hosein, Shaikh, Masood Ali, Shamshirian, Amir, Shamsizadeh, Morteza, Shirkoohi, Reza, Siabani, Soraya, Singh, Jasvinder A., SiRamlee, Khairil, Tabarés-Seisdedos, Rafael, Temsah, Mohamad-Hani, Tran, Bach Xuan, Ullah, Irfan, Vahedian-Azimi, Amir, Vollset, Stein Emil, Vos, Theo, Waheed, Yasir, Weldesamuel, Girmay Teklay, Workie, Hailemariam Mekonnen, Xu, Rixing, Yaseri, Mehdi, Yonemoto, Naohiro, Yu, Chuanhua, Zadnik, Vesna, Zahirian Moghadam, Telma, Zaidi, Zoubida, Zangeneh, Alireza, Zewale, Taye Abuhay, Ziapour, Arash, Zodpey, Sanjay, Murray, Christopher J L, Fitzmaurice, Christina, and Bhakta, Nickhill

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results